Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)

Nevitt SJ, Marson AG, Weston J, Tudur Smith C.


www.cochranelibrary.com
# Table of Contents

- **Header**.......................................................... 1
- **Abstract**...................................................... 1
- **Plain Language Summary**................................. 2
- **Summary of Findings for the Main Comparison**......... 4
- **Background**.................................................. 6
- **Objectives**................................................... 7
- **Methods**....................................................... 7
- **Results**........................................................ 10
  - Figure 1. ....................................................... 11
  - Figure 2. ....................................................... 13
  - Figure 3. ....................................................... 14
  - Figure 4. ....................................................... 17
  - Figure 5. ....................................................... 18
  - Figure 6. ....................................................... 19
  - Figure 7. ....................................................... 20
  - Figure 8. ....................................................... 21
  - Figure 9. ....................................................... 22
  - Figure 10. ..................................................... 23
  - Figure 11. ..................................................... 24
  - Figure 12. ..................................................... 26
  - Figure 13. ..................................................... 28
  - Figure 14. ..................................................... 30
- **Additional Summary of Findings**.......................... 31
- **Discussion**.................................................. 37
- **Authors' Conclusions**...................................... 39
- **Acknowledgements**.......................................... 40
- **References**................................................ 44
- **Characteristics of Studies**................................ 62
- **Data and Analyses**.......................................... 63
  - Analysis 1.1. Comparison 1 Carbamazepine versus phenytoin, Outcome 1 Time to withdrawal of allocated treatment. 63
  - Analysis 1.2. Comparison 1 Carbamazepine versus phenytoin, Outcome 2 Time to withdrawal of allocated treatment - stratified by epilepsy type. 64
  - Analysis 1.3. Comparison 1 Carbamazepine versus phenytoin, Outcome 3 Time to achieve 12-month remission. 65
  - Analysis 1.4. Comparison 1 Carbamazepine versus phenytoin, Outcome 4 Time to achieve 12-month remission - stratified by epilepsy type. 66
  - Analysis 1.5. Comparison 1 Carbamazepine versus phenytoin, Outcome 5 Time to achieve six-month remission. 67
  - Analysis 1.6. Comparison 1 Carbamazepine versus phenytoin, Outcome 6 Time to achieve six-month remission - stratified by epilepsy type. 68
  - Analysis 1.7. Comparison 1 Carbamazepine versus phenytoin, Outcome 7 Time to first seizure post-randomisation. 69
  - Analysis 1.8. Comparison 1 Carbamazepine versus phenytoin, Outcome 8 Time to first seizure post-randomisation - stratified by epilepsy type. 70
- **Additional Tables**........................................... 70
- **Appendices**................................................ 77
- **What's New**................................................ 80
- **History**...................................................... 80
- **Contributions of Authors**................................ 81
- ** Declarations of Interest**................................. 81
- **Sources of Support**......................................... 81
- ** Differences Between Protocol and Review**............. 82
- **Notes**........................................................ 82
- **Index Terms**................................................ 82
Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review

Sarah J Nevitt¹, Anthony G Marson², Jennifer Weston², Catrin Tudur Smith¹

¹Department of Biostatistics, University of Liverpool, Liverpool, UK. ²Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK

Contact address: Sarah J Nevitt, Department of Biostatistics, University of Liverpool, Block F, Waterhouse Building, 1-5 Brownlow Hill, Liverpool, L69 3GL, UK. sjn16@liverpool.ac.uk.

Editorial group: Cochrane Epilepsy Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 2, 2017.


ABSTRACT

Background

This is an updated version of the original Cochrane Review published in Issue 2, 2002 and its subsequent updates in 2010 and 2015. Epilepsy is a common neurological condition in which recurrent, unprovoked seizures are caused by abnormal electrical discharges from the brain. It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to become seizure-free and go into long-term remission shortly after starting drug therapy with a single antiepileptic drug in monotherapy.

Worldwide, carbamazepine and phenytoin are commonly-used broad spectrum antiepileptic drugs, suitable for most epileptic seizure types. Carbamazepine is a current first-line treatment for partial onset seizures in the USA and Europe. Phenytoin is no longer considered a first-line treatment due to concerns over adverse events associated with its use, but the drug is still commonly used in low- to middle-income countries because of its low cost. No consistent differences in efficacy have been found between carbamazepine and phenytoin in individual trials, although the confidence intervals generated by these studies are wide. Differences in efficacy may therefore be shown by synthesising the data of the individual trials.

Objectives

To review the time to withdrawal, six- and 12-month remission, and first seizure with carbamazepine compared to phenytoin, used as monotherapy in people with partial onset seizures (simple partial, complex partial, or secondarily generalised tonic-clonic seizures), or generalised tonic-clonic seizures, with or without other generalised seizure types.

Search methods

For the latest update we searched the Cochrane Epilepsy Group’s Specialised Register (1st November 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 1st November 2016), MEDLINE (Ovid, 1946 to 1 November 2016), ClinicalTrials.gov (1 November 2016), and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP, 1st November 2016). Previously we also searched SCOPUS (1823 to 16th September 2014) as an alternative to Embase, but this is no longer necessary, because randomised and quasi-randomised controlled trials in Embase are now included in CENTRAL. We handsearched relevant journals, contacted pharmaceutical companies, original trial investigators and experts in the field.
Selection criteria

Randomised controlled trials (RCTs) in children or adults with partial onset seizures or generalised onset tonic-clonic seizures, comparing carbamazepine monotherapy versus phenytoin monotherapy.

Data collection and analysis

This is an individual participant data (IPD) review. Our primary outcome was time to withdrawal of allocated treatment, and our secondary outcomes were time to six-month remission, time to 12-month remission, and time to first seizure post-randomisation. We used Cox proportional hazards regression models to obtain study-specific estimates of hazard ratios (HRs) with 95% confidence intervals (CIs) and the generic inverse variance method to obtain the overall pooled HR and 95% CI.

Main results

IPD were available for 595 participants out of 1192 eligible individuals, from four out of 12 trials (i.e. 50% of the potential data). For remission outcomes, HR greater than 1 indicates an advantage for phenytoin; and for first seizure and withdrawal outcomes, HR greater than 1 indicates an advantage for carbamazepine. The methodological quality of the four studies providing IPD was generally good and we rated it at low risk of bias overall in the analyses.

The main overall results (pooled HR adjusted for seizure type) were time to withdrawal of allocated treatment: 1.04 (95% CI 0.78 to 1.39; three trials, 546 participants); time to 12-month remission: 1.01 (95% CI 0.78 to 1.31; three trials, 551 participants); time to six-month remission: 1.11 (95% CI 0.89 to 1.37; three trials, 551 participants); and time to first seizure: 0.85 (95% CI 0.70 to 1.04; four trials, 582 participants). The results suggest no overall statistically significant difference between the drugs for these outcomes. There is some evidence of an advantage for phenytoin for individuals with generalised onset seizures for our primary outcome (time to withdrawal of allocated treatment): pooled HR 0.42 (95% CI 0.18 to 0.96; two trials, 118 participants); and a statistical interaction between treatment effect and epilepsy type (partial versus generalised) for this outcome (P = 0.02). However, misclassification of seizure type for up to 48 individuals (32% of those with generalised epilepsy) may have confounded the results of this review. Despite concerns over side effects leading to the withdrawal of phenytoin as a first-line treatment in the USA and Europe, we found no evidence that phenytoin is more likely to be associated with serious side effects than carbamazepine; 26 individuals withdrew from 290 randomised (9%) to carbamazepine due to adverse effects, compared to 12 out of 299 (4%) randomised to phenytoin from four studies conducted in the USA and Europe (risk ratio (RR) 1.42, 95% CI 1.13 to 1.80, P = 0.014). We rated the quality of the evidence as low to moderate according to GRADE criteria, due to imprecision and potential misclassification of seizure type.

Authors’ conclusions

We have not found evidence for a statistically significant difference between carbamazepine and phenytoin for the efficacy outcomes examined in this review, but CIs are wide and we cannot exclude the possibility of important differences. There is no evidence in this review that phenytoin is more strongly associated with serious adverse events than carbamazepine. There is some evidence that people with generalised seizures may be less likely to withdraw early from phenytoin than from carbamazepine, but misclassification of seizure type may have impacted upon our results. We recommend caution when interpreting the results of this review, and do not recommend that our results alone should be used in choosing between carbamazepine and phenytoin. We recommend that future trials should be designed to the highest quality possible, with considerations of allocation concealment and masking, choice of population, choice of outcomes and analysis, and presentation of results.

Plain Language Summary

Carbamazepine versus phenytoin (given as a single drug treatment) for epilepsy

Background

Epilepsy is a common neurological disorder in which recurrent seizures are caused by abnormal electrical discharges from the brain. We studied two types of epileptic seizures in this review: generalised onset seizures in which electrical discharges begin in one part of the brain and move throughout the brain, and partial onset seizures in which the seizure is generated in and affects only one part of the brain (the whole hemisphere of the brain or part of a lobe of the brain). For around 70% of people with epilepsy, generalised onset or partial onset seizures can be controlled by a single antiepileptic drug. Worldwide, phenytoin and carbamazepine are commonly used antiepileptic drugs, although carbamazepine is used more commonly in the USA and Europe due to concerns over side effects.
associated with phenytoin. Phenytoin is still commonly used in low- and middle-income countries in Africa, Asia and South America, because of the low cost of the drug.

**Objective**

For this updated review, we looked at the evidence from 12 randomised controlled clinical trials comparing phenytoin and carbamazepine based on how effective the drugs were at controlling seizures (i.e. whether people went back to having seizures or had long periods of freedom from seizures (remission)), and how tolerable any related side effects of the drugs were.

**Main results**

We were able to combine data for 595 people from four of the 12 trials; for the remaining 597 people from eight trials, information was not available to use in this review. The evidence is current to November 2016.

Results of this review suggest that people with generalised seizures are more likely to withdraw from carbamazepine treatment earlier than from phenytoin treatment, due to seizure recurrence, side effects of the drug, or both, but for people with partial seizures there was no difference in times of withdrawal from treatment between the two drugs. Even though phenytoin is thought to cause more and worse side effects than carbamazepine, we found that twice as many people withdrew from treatment with carbamazepine due to side effects than from treatment with phenytoin.

Results of the review show no difference between carbamazepine and phenytoin for people achieving long periods of seizure freedom (six- or 12-month remission of seizures), or experiencing more seizures after starting treatment.

We judge the evidence from this review to be of low to moderate quality. We recommend that caution is used when interpreting the results of this review, as we were unable to combine the data for all people treated in trials comparing carbamazepine to phenytoin. Also, up to 30% of people in the trials used in our results may have been wrongly classified as having generalised seizures; this may have affected the results of our review.

We recommend that any future trials comparing these drugs, or any other antiepileptic drugs, should be designed using high-quality methods, and that the seizure types of people included in trials should be classified very carefully, to ensure results are of high quality.
## Summary of Findings for the Main Comparison

### Carbamazepine compared with phenytoin for epilepsy

**Patient or population:** adults and children with new-onset partial or generalised epilepsy  
**Settings:** outpatients  
**Intervention:** carbamazepine  
**Comparison:** phenytoin

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)(^1)</th>
<th>No. of Participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Assumed risk</td>
<td>Corresponding risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phenytoin</td>
<td>37 per 100</td>
<td>35 per 100 (28 to 44)</td>
<td>HR 1.04 (0.78 to 1.39)</td>
<td>546 (3 studies)</td>
<td>⊕⊕⊕ ⊕ moderate(^2,3)</td>
</tr>
</tbody>
</table>
|          | Time to withdrawal of allocated treatment - stratified by epilepsy type  
Range of follow-up (all participants): 1 day to 4403 days |                  |                             |                                |          |
| Carbamazepine| 37 per 100                             | 35 per 100 (28 to 44)         | HR 1.18 (0.87 to 1.60)      | 428 (3 studies)                | ⊕⊕⊕ ⊕ moderate\(^2,3\) | HR > 1 indicates a clinical advantage for carbamazepine |
|          | Time to withdrawal of allocated treatment - partial epilepsy  
Range of follow-up (all participants): 1 day to 4064 days |                  |                             |                                |          |
|          | 14 per 100                             | 30 per 100 (15 to 57)         | HR 0.42 (0.18 to 0.96)      | 118 (2 studies)                | ⊕⊕⊕ ⊕ moderate\(^2,3\) | HR > 1 indicates a clinical advantage for carbamazepine |
|          | Time to withdrawal of allocated treatment - generalised epilepsy  
Range of follow-up (all participants): 1 day to 4403 days |                  |                             |                                |          |
### Table

| Proportion of withdrawals due to adverse effects | Range of follow-up (all participants): 1 day to 4403 days | RR 1.42 (1.13 to 1.80) | 546 (3 studies) | ★★★★ moderate² | RR < 1 indicates a clinical advantage for carbamazepine

---

**Proportion of withdrawals due to adverse effects**

| 4 per 100 | 6 per 100 (5 to 7) |

---

*The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The assumed risk is calculated as the event rate in the phenytoin treatment group. The corresponding risk in the carbamazepine treatment group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). The corresponding risk is calculated as the assumed risk x the relative risk (RR) of the intervention where RR = (1 - exp(HR x ln(1 - assumed risk)))) / assumed risk.

CI: confidence interval; RR: risk ratio; HR: hazard ratio; exp: exponential

<table>
<thead>
<tr>
<th>GRADE Working Group grades of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>High quality: Further research is very unlikely to change our confidence in the estimate of effect.</td>
</tr>
<tr>
<td>Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.</td>
</tr>
<tr>
<td>Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.</td>
</tr>
<tr>
<td>Very low quality: We are very uncertain about the estimate.</td>
</tr>
</tbody>
</table>

---

1. Pooled HR for all participants adjusted for seizure type.
2. Risk of bias unclear for one element of all of the three studies included in the analysis. De Silva 1996 and Heller 1995 are open-label and it is unclear whether the lack of masking impacted upon the results; and we do not know how allocation was concealed in Mattson 1985.
3. 29 adult participants in Heller 1995 may have had their seizure type wrongly classified as generalised onset; sensitivity analyses show misclassification may have had an impact on results and conclusions regarding an association between treatment and seizure type.
BACKGROUND

This review is an update of a previously published review in the Cochrane Database of Systematic Reviews (see Other published versions of this review).

Description of the condition

Epilepsy is a common neurological condition in which recurrent, unprovoked seizures are caused by abnormal electrical discharges from the brain. Epilepsy is a disorder of many heterogeneous seizure types, with an estimated incidence of 33 to 57 per 100,000 person-years worldwide (Annegers 1999; Hirtz 2007; MacDonald 2000; Olafsson 2005; Sander 1996), accounting for approximately 1% of the global burden of disease (Murray 1994). The lifetime risk of epilepsy onset is estimated to be 1300 to 4000 per 100,000 person-years (Hauser 1993; Juul-Jensen 1983), and the lifetime prevalence could be as large as 70 million people worldwide (Ngugi 2010). It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to become seizure-free and go into long-term remission shortly after starting drug therapy (Cockerell 1995; Hauser 1993; Sander 2004), and that around 70% of individuals can achieve seizure freedom using a single antiepileptic drug in monotherapy (Cockerell 1995); current National Institute for Health and Clinical Excellence (NICE) guidelines recommend that both adults and children with epilepsy should be treated by monotherapy wherever possible (NICE 2012). The remaining 30% of individuals experience refractory or drug-resistant seizures which often require treatment with combinations of antiepileptic drugs, or alternative treatments such as epilepsy surgery (Kwan 2000).

We study two seizure types in this review: generalised onset seizures (generalised tonic-clonic seizures with or without other generalised seizure types), in which electrical discharges begin in one part of the brain and move throughout the brain; and partial onset seizures, in which the seizure is generated in and affects only one part of the brain (the whole hemisphere of the brain or part of a lobe of the brain).

Description of the intervention

Carbamazepine and phenytoin are among the most commonly used and earliest drugs licensed for the treatment of epileptic seizures; phenytoin has been used as monotherapy for partial seizures and generalised tonic-clonic seizures for over 50 years (Gruber 1962) and carbamazepine for over 30 years (Shakir 1980). Current NICE guidelines (NICE 2012) for adults and children recommend carbamazepine as a first-line treatment for partial onset seizures and as a second-line treatment for generalised tonic-clonic seizures if first-line treatments sodium valproate and lamotrigine are deemed unsuitable; however, there is evidence that carbamazepine may exacerbate some other generalised seizure types such as myoclonic and absence seizures (Liporace 1994; Shields 1983; Snead 1985). Phenytoin is no longer considered a first-line treatment in the USA and most of Europe, due to concerns over adverse events (Wallace 1997; Wilder 1995), but phenytoin is still used as a first-line drug in low- to middle-income countries (Ogunrin 2005; Pal 1998). Both carbamazepine and phenytoin have been shown to have teratogenic effects where the risk is estimated to be two to three times that of the general population (Gladstone 1992; Meador 2008; Morrow 2006; Nulman 1997). Carbamazepine is associated particularly with neural tube defects (Matlow 2012) and phenytoin is associated with fetal hydantoin syndrome (Scheinfeld 2003), low folic acid levels and megaloblastic anaemia (Carl 1992). Both carbamazepine and phenytoin are associated with an allergic rash (Tennis 1997) in 5% to 10% of users, which on rare occasions may be life-threatening, and phenytoin is also associated with long-term cosmetic changes including gum hyperplasia, acne and coarsening of the facial features (Mattson 1985; Scheinfeld 2003).

How the intervention might work

Antiepileptic drugs suppress seizures by reducing neuronal excitability. Phenytoin and carbamazepine are broad-spectrum treatments suitable for many seizure types and both have an anticonvulsant mechanism through blocking ion channels, binding with neurotransmitter receptors or through inhibiting the metabolism or reuptake of neurotransmitters (Ragsdale 1991; Willow 1985) and the modulation of gamma-aminobutyric acid-A (GABA-A) receptors (Granger 1995).

Why it is important to do this review

The aim of this review is to summarise efficacy and tolerability data from existing trials comparing carbamazepine and phenytoin when used as monotherapy treatments. The adverse event profiles of the two drugs are well documented (see example references from Description of the intervention), but no consistent differences in efficacy have been found between the two drugs from a number of randomised controlled trials (RCTs) individually (for example: De Silva 1996; Heller 1995; Mattson 1985; Ramsay 1983). Although no clear difference in efficacy has been found from individual studies, the confidence intervals generated by these studies are wide. We cannot exclude important differences in efficacy, which may be shown by synthesising the data of the individual trials. There are difficulties in undertaking a systematic review of epilepsy monotherapy trials, as the important efficacy outcomes require analysis of time-to-event data (for example, time to first seizure after randomisation). Although methods have been developed to synthesise time-to-event data using summary information (Parmar 1998; Williamson 2002), the appropriate statistics are not commonly reported in published epilepsy trials (Nolan 2013a). Fur-
thermore, although seizure data have been collected in most epilepsy monotherapy trials, there has been no uniformity in the definition and reporting of outcomes. For example, trials may report time to 12-month remission but not time to first seizure or vice versa, or some trials may define time to first seizure from the date of randomisation, while others use date of achieving a maintenance dose. Trial investigators have also adopted differing approaches to the analysis, particularly with respect to the censoring of time-to-event data. For these reasons, we performed this review using individual participant data (IPD), which helps to overcome these problems. This review is one in a series of Cochrane IPD Reviews investigating pair-wise monotherapy comparisons. These data have also been included in a network meta-analysis (Tudur Smith 2007), undertaken following a previous version of this review.

OBJECTIVES

To review the time to withdrawal, six- and 12-month remission, and first seizure with carbamazepine compared to phenytoin, used as monotherapy in people with partial onset seizures (simple partial, complex partial, or secondarily generalised tonic-clonic seizures) or generalised tonic-clonic seizures, with or without other generalised seizure types.

METHODS

Criteria for considering studies for this review

Types of studies

1. Studies must be randomised controlled trials (RCTs) using either an adequate method of allocation concealment (e.g. sealed opaque envelopes) or a quasi-randomised method of allocation (e.g. allocation by date of birth).
2. Studies must be of parallel design; cross-over studies are not an appropriate design for measuring the long-term outcomes of interest in this review (see Types of outcome measures).
3. Studies must include a comparison of carbamazepine monotherapy with phenytoin monotherapy in individuals with epilepsy; cluster-randomised studies are therefore not an eligible design.

We included studies regardless of blinding method (unblinded, single-blind or double-blind).

Types of participants

1. We included trials recruiting children or adults with partial onset seizures (simple partial, complex partial, or secondarily generalised tonic-clonic seizures) or generalised onset tonic-clonic seizures (as a primary generalised seizure type), with or without other generalised seizure types (e.g. absence, myoclonic, etc.).
2. We excluded studies that recruited only individuals with other generalised seizure types, without generalised tonic-clonic seizures (such as studies recruiting only individuals with a diagnosis of absence seizures or juvenile myoclonic epilepsy, etc.) due to differences in first-line treatment guidelines (NICE 2012).
3. We included individuals who had a new diagnosis of epilepsy or who had experienced a relapse following antiepileptic monotherapy withdrawal only, due to differences in first-line treatment guidelines for individuals with refractory epilepsy (NICE 2012).

Types of interventions

Carbamazepine versus phenytoin (any doses) as monotherapy.

Types of outcome measures

We present the outcomes investigated in this review. Reporting of these outcomes in the original trial report was not an eligibility requirement for this review:

Primary outcomes

1. Time to withdrawal of allocated treatment (retention time) is the primary outcome. This is a combined outcome, reflecting both efficacy and tolerability, as treatment may be withdrawn due to continued seizures, side effects, non-compliance or if additional add-on treatment was initiated (i.e. allocated treatment had failed). This is an outcome to which the participant makes a contribution, and is the primary outcome measure recommended by the Commission on Antiepileptic Drugs of the International League Against Epilepsy (Commission 1998; ILAE 2006).

Secondary outcomes

1. Time to achieve 12-month remission (seizure-free period).
2. Time to achieve six-month remission (seizure-free period).
3. Time to first seizure post-randomisation.
4. Adverse events (including those relating to treatment withdrawal)

Search methods for identification of studies

Electronic searches
We conducted searches for the original review in 1999, and subsequently in 2001, 2003, 2005, July 2007, November 2009, November 2011, October 2013, and September 2014. For the latest update we searched the following databases, applying no language restrictions:

- The Cochrane Epilepsy Group’s Specialized Register (1st November 2016), using the search strategy outlined in Appendix 1.
- The Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 1st November 2016), using the search strategy outlined in Appendix 2.
- MEDLINE (Ovid, 1946 to 1st November 2016), using the search strategy outlined in Appendix 3.
- ClinicalTrials.gov (1st November 2016), using the search terms ‘carbamazepine and phenytoin and epilepsy | Studies received on or after 09/16/2014’.
- World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP, 1st November 2016), using the search terms ‘carbamazepine and phenytoin and epilepsy not NCT*’ (new items selected manually).

Previously we also searched SCOPUS (1823 to 16th September 2014), using the search strategy outlined in Appendix 4, as an alternative to Embase, but this is no longer necessary, because randomised and quasi-randomised controlled trials in Embase are now included in CENTRAL.

Searching other resources

In addition, we handsearched relevant journals, reviewed the reference lists of retrieved studies to search for additional reports of relevant studies, contacted Novartis (manufacturers of carbamazepine), Parke-Davis (manufacturers of phenytoin), and experts in the field for information on any ongoing studies, and original investigators of relevant trials found.

Data collection and analysis

Selection of studies

Two review authors (SJN and AGM) independently assessed trials for inclusion, resolving any disagreements by discussion.

Data extraction and management

We requested the following individual participant data (IPD) for all trials meeting our inclusion criteria:

Trial methods:
- method of generation of random list
- method of concealment of randomisation
- stratification factors

Participant covariates:
- gender
- age
- seizure types
- time between first seizure and randomisation
- number of seizures prior to randomisation (with dates)
- presence of neurological signs
- electroencephalographic (EEG) results
- computerised tomography/magnetic resonance imaging (CT/MRI) results

Follow-up data:
- treatment allocation
- date of randomisation
- dates of follow-up
- dates of seizures post-randomisation or seizure frequency
- data between follow-up visits
- dates of treatment withdrawal and reasons for treatment withdrawal
- dose
- dates of dose changes

For each trial for which we did not obtain IPD, we carried out an assessment to see whether any relevant aggregate-level data had been reported.

In one study (Mattson 1985), seizure data were provided in terms of the number of seizures recorded between each follow-up visit rather than specific dates of seizures. To enable us to calculate time-to-event outcomes, we applied linear interpolation to approximate dates of seizures between follow-up visits, assuming a uniform seizure rate. For example, if four seizures were recorded between two visits which occurred on 1st March 1990 and 1st May 1990 (an interval of 61 days), then the date of first seizure would be approximately 13th March 1990 (i.e. 61 days divided by number of seizures plus 1 rounded to the next day, i.e. 13 days). This allowed us to compute an estimate of the time to six-month remission, 12-month remission, and the time to first seizure. We calculated time to six-month and 12-month remission from the date of randomisation to the date (or estimated date) the individual had first been free of seizures for six or 12 months respectively. If the person had one or more seizures in the titration period, a six-month or 12-month seizure-free period could also occur between the estimated date of the last seizure in the titration period and the estimated date of the first seizure in the maintenance period.

We calculated time to first seizure from the date of randomisation to the date that their first seizure was estimated to have occurred. If seizure data were missing for a particular visit, we censored these outcomes at the previous visit. We also censored these outcomes if the individual died or if follow-up ceased prior to the occurrence of the event of interest. These methods had been used in the remaining three trials (De Silva 1996; Heller 1995; Ogunrin 2005).
for which outcome data (dates of seizures after randomisation) were provided directly.
In one trial (Ogunrin 2005), all participants completed the 12-week trial duration without withdrawing from the study. For three trials (De Silva 1996; Heller 1995; Mattson 1985) we extracted dates and reason for treatment withdrawal from trial case report forms for the original review. Two review authors (SJN and CT) independently extracted data from all case report forms, resolving disagreements by reconsidering the case report forms at conference. For the remaining trials, data on length of time spent in trial and reason for withdrawal of allocated treatment were provided directly. For the analysis of time to event, we defined an ‘event’ as either the withdrawal of the allocated treatment due to poor seizure control, or adverse events, or both. We also classified non-compliance with the treatment regimen or the addition of another antiepileptic drug as ‘events’. We censored the outcome if treatment was withdrawn because the individual achieved a period of remission, or if the individual was still on allocated treatment at the end of follow-up.

Assessment of risk of bias in included studies

Two review authors (SJN and JW) independently assessed all included studies for risks of bias (Higgins 2011), resolving any disagreements by discussion. The domains assessed as being at low, high or unclear risk of bias were random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other potential sources of bias. We took into account all available information for an included study when making risk of bias judgements, including multiple publications of the study and additional information provided from study authors with IPD.

Measures of treatment effect
We measured all outcomes in this review as time-to-event outcomes with the hazard ratio (HR). We calculated outcomes from IPD provided where possible or extracted summary statistics from published studies.

Unit of analysis issues
We did not have any unit of analysis issues. The unit of allocation and analysis was the individual participant for all included studies and no studies were of a cross-over design.

Dealing with missing data
For each trial where IPD were supplied, we reproduced information from trial results where possible, and performed the following consistency checks:

- We cross-checked trial details against any published report of the trial and contacted original trial authors if we found missing data, errors or inconsistencies.
- We reviewed the chronological randomisation sequence, and checked the balance of participant characteristics, taking account of factors stratified for in the randomisation procedure.

Assessment of heterogeneity

We assessed heterogeneity statistically using the Q test (P value < 0.10 for significance) and the I² statistic (Higgins 2003) (greater than 50% indicating considerable heterogeneity), output produced using the generic inverse variance approach in Metaview, and visually by inspecting forest plots.

Assessment of reporting biases

Two review authors (SJN and JP) undertook all full quality and risk of bias assessments. In theory, a review using IPD should overcome issues of reporting biases, as unpublished data can be provided and unpublished outcomes calculated. Any selective reporting bias detected could be assessed with the ORBIT classification system (Kirkham 2010).

Data synthesis

We carried out our analysis on an intention-to-treat basis (that is, analysing participants in the group to which they were randomised, irrespective of which treatment they actually received). For the time-to-event outcomes ‘Time to six-month remission’, ‘Time to 12-month remission’ and ‘Time to first seizure post-randomisation’, participants were therefore not censored if the treatment initially assigned was withdrawn.

For all outcomes, we investigated the relationship between the time-to-event and treatment effect of the antiepileptic drugs. We used Cox proportional hazards regression models to obtain study-specific estimates of log (HR) or treatment effect and associated standard errors in statistical software SAS version 9.2 (Copyright, SAS Institute Inc. SAS and all other SAS Institute Inc. product or service names are registered trademarks or trademarks of SAS Institute Inc., Cary, NC, USA.). The model assumes that the ratio of hazards (risks) between the two treatment groups is constant over time (i.e. hazards are proportional). We tested this proportional hazards assumption of the Cox regression model for each outcome of each study by testing the statistical significance of a time-varying covariate in the model. We also inspected Kaplan-Meier plots for overlapping of curves, which can indicate departures from proportional hazards. We evaluated overall estimates of HRs (with 95% confidence intervals (CIs)) using the generic inverse variance method. We expressed results as a hazard ratio (HR) with 95% CIs.

By convention, a HR greater than 1 indicates that an event is more likely to occur earlier with carbamazepine than with phenytoin.
Hence, for time to withdrawal of allocated treatment or time to first seizure, a HR greater than 1 indicates a clinical advantage for phenytoin (e.g. HR = 1.2 would suggest a 20% increase in the risk of withdrawal from carbamazepine compared to phenytoin) and for time to six-month and 12-month remission a HR greater than 1 indicates a clinical advantage for carbamazepine.

We used GRADE (GRADE 2004) quality assessment criteria in the 'Summary of findings' tables.

**Subgroup analysis and investigation of heterogeneity**

Due to the strong clinical belief that some antiepileptic drugs are more effective in some seizure types than others (see Description of the intervention and How the intervention might work), we have stratified all analyses by seizure type (partial onset versus generalised onset), according to the classification of main seizure type at baseline. We classified partial seizures (simple or complex) and partial secondarily generalised seizures as partial epilepsy. We classified primarily generalised seizures as generalised epilepsy. To statistically assess an association between treatment and seizure type we conducted a Chi$^2$ test of interaction between treatment and epilepsy type.

If we found significant statistical heterogeneity to be present, we performed meta-analysis with a random-effects model in addition to a fixed-effect model, presenting the results of both models and performing sensitivity analyses to investigate differences in study characteristics.

**Sensitivity analysis**

Misclassification of seizure type is a recognised problem in epilepsy, whereby some people with generalised seizures have been mistakenly classed as having partial onset seizures, and vice versa. There is clinical evidence that individuals with generalised onset seizures are unlikely to have an ‘age of onset’ greater than 25 to 30 years (Malafosse 1994). In a previous review, in our series of pair-wise reviews for monotherapy in epilepsy, misclassification impacted upon the results (Nolan 2013b). Given the overlap with studies contributing to this review and the phenytoin versus sodium valproate review (Nolan 2013b), we suspected that misclassification of seizure type could also be likely in this review, and so we examined the distribution of age at onset for individuals with generalised seizures.

De Silva 1996 was a paediatric study and Mattson 1985 recruited participants with partial seizures only, so there were no participants with new-onset generalised seizures over the age of 30 in these studies. Twenty-nine out of 72 individuals (42%) with generalised onset seizures were over the age of 30 in Heller 1995, and 19 out of 29 individuals (66%) with generalised onset seizures were over the age of 30 in Ogunrin 2005. Therefore out of 150 participants from the four studies providing IPD, 48 (32%) may have been wrongly classified as having new-onset generalised seizures.

We undertook the following two sensitivity analyses to investigate misclassification for each outcome:

1. We reclassified the 48 individuals with generalised seizure types and age at onset greater than 30 into an ‘uncertain seizure type’ group.

2. We reclassified the 48 individuals with generalised seizures and age of onset greater than 30 as having partial seizures.

**RESULTS**

**Description of studies**

**Results of the search**

We identified 655 records from the databases and search strategies outlined in Electronic searches. We found three further records by handsearching and checking reference lists of included studies. We removed 265 duplicate records and screened 393 records (title and abstract) for inclusion in the review. We excluded 354 records based on title and abstract and assessed 39 full-text articles for inclusion in the review. We excluded 14 studies (reported in 20 full-text articles) from the review (see Excluded studies below) and included 12 trials (reported in 18 full-text articles) in the review (see Included studies below). One study is awaiting classification following translation (Rysz 1994). See Figure 1 for PRISMA study flow diagram (Moher 2009).
Figure 1. Study flow diagram.

- 655 records identified through database searching
- 3 additional records identified through other sources (handsearching and reference lists)

265 duplicate records removed

393 records screened (title and abstract)

354 records excluded

14 studies (reported in 20 full-text articles) excluded:
- Not randomised (N = 7)
- Not monotherapy (N = 5)
- No randomised comparison between carbamazepine and phenytoin (N = 2)

1 full-text article (awaiting translation from Polish) awaiting classification

39 full-text articles assessed for eligibility

12 studies (reported in 18 full-text articles) included in qualitative synthesis

4 studies included in quantitative synthesis (meta-analysis)
Included studies

We included 12 trials in this review (Callaghan 1985; Cereghino 1974; Czapinski 1997; De Silva 1996; Forsythe 1991; Heller 1995; Mattson 1985; Miura 1993; Ogunrin 2005; Pulliainen 1994; Ramsay 1983; Ravi Sudhir 1995). One trial was available in abstract form only (Czapinski 1997).

One trial recruited individuals of all ages (Callaghan 1985), three trials recruited children only (defined as under the age of 16 in De Silva 1996, and under the age of 14 in Forsythe 1991 and Miura 1993); and the remaining eight trials recruited adults only. Four trials defined adults as individuals above the age of 18 (Cereghino 1974; Czapinski 1997; Mattson 1985; Ramsay 1983), one trial classified adults as older than 13 years (Heller 1995), two trials classified adults as older than 14 years (Ogunrin 2005; Ravi Sudhir 1995) and one trial classified adults as older than 15 years (Pulliainen 1994).

Ten trials recruited individuals with partial onset seizures and generalised onset seizures (Callaghan 1985; Cereghino 1974; De Silva 1996; Forsythe 1991; Heller 1995; Miura 1993; Ogunrin 2005; Pulliainen 1994; Ramsay 1983; Ravi Sudhir 1995), and two trials recruited individuals with partial onset seizures only (Czapinski 1997; Mattson 1985). Ten trials recruited individuals with new-onset seizures or previously untreated seizures, or both (Callaghan 1985; Czapinski 1997; De Silva 1996; Forsythe 1991; Heller 1995; Miura 1993; Ogunrin 2005; Pulliainen 1994; Ramsay 1983; Ravi Sudhir 1995). One trial recruited institutionalised participants with uncontrolled seizures (Cereghino 1974), and one trial recruited "previously untreated or under treated" individuals (Mattson 1985).

Six trials were conducted in Europe (Callaghan 1985; Czapinski 1997; De Silva 1996; Forsythe 1991; Heller 1995; Pulliainen 1994), three in the USA (Cereghino 1974; Mattson 1985; Ramsay 1983), one in Nigeria (Ogunrin 2005), one in India (Ravi Sudhir 1995), and one in Japan (Miura 1993).

Individual participant data (IPD) could not be supplied for eight trials (Callaghan 1985; Cereghino 1974; Czapinski 1997; Forsythe 1991; Miura 1993; Pulliainen 1994; Ramsay 1983; Ravi Sudhir 1995), in which 597 individuals had been randomised to either phenytoin or carbamazepine. None of these eight trials reported the specific time-to-event outcomes chosen for this systematic review.

Forsythe 1991 presented times at which the allocated drug was withdrawn and the reason for withdrawal in the trial publication for each individual. Hence, we were able to incorporate this trial into the analysis of 'Time to withdrawal of allocated treatment'. For each participant, 'withdrawal and time of occurrence by month' was presented and therefore to calculate 'Time to withdrawal of allocated treatment' we assumed that, for example, if withdrawal occurred during the fifth month, that withdrawal occurred halfway between the fifth and sixth month (i.e. participants spent 167 full days on treatment before withdrawal).

We could not extract sufficient aggregate data from the trial publication in any other trial, and we therefore could not include them in data synthesis. Full details of outcomes considered and a summary of results in each eligible trial for which IPD were not available can be found in Table 1.

IPD were provided by trial authors for the four remaining trials which recruited 595 participants, representing 49.9% of individuals from 1192 individuals in all eligible trials (De Silva 1996; Heller 1995; Mattson 1985; Ogunrin 2005). Two trials (Mattson 1985; Ogunrin 2005) directly provided computerised data, and the authors of the other two trials (Heller 1995; De Silva 1996) supplied a combination of both computerised and paper-based (although mostly computerised) data.

Data were available for the following subject characteristics (percentage of 595 participants with data available): sex (100%), seizure type (100%), drug randomised (99% - data missing for six participants in De Silva 1996), sex (99% - data missing for eight participants), age at randomisation (98% - data missing for nine participants), number of seizures in six months prior to randomisation (98% - data missing for 11 participants), time since first seizure to randomisation (98% - data missing for 10 participants). The results of neurological examinations were provided for 326 participants (55%) from three trials (De Silva 1996; Heller 1995; Ogunrin 2005), electroencephalographic (EEG) results were provided for 316 participants (53%) from one trial (Mattson 1985) and computerised tomography/magnetic resonance imaging (CT/MRI) results were provided for 324 participants (54%) in two trials (Mattson 1985; Ogunrin 2005).

Excluded studies

We excluded five studies which were not RCTs (Bird 1966; Kuzuya 1993; Sabers 1995; Shorvon 1978; Zeng 2010). We excluded seven trials which did not use carbamazepine and phenytoin in monotherapy (Bittencourt 1993; Canadian Study 1998; Hakami 2012; Kosteljanetz 1979; Rajotte 1967; Simonsen 1976; Troupin 1975), and we excluded two trials which did not make a randomised comparison between carbamazepine and phenytoin monotherapy (Kaminow 2003; Shakir 1980). See Characteristics of excluded studies for further details.

Risk of bias in included studies

For further details see Characteristics of included studies, Figure 2 and Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as percentages across all included studies.
Figure 3. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

<table>
<thead>
<tr>
<th>Study</th>
<th>Random sequence generation (selection bias)</th>
<th>Allocation concealment (selection bias)</th>
<th>Blinding of participants and personnel (performance bias)</th>
<th>Blinding of outcome assessment (detection bias)</th>
<th>Incomplete outcome data (attrition bias)</th>
<th>Selective reporting (reporting bias)</th>
<th>Other bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Silva 1996</td>
<td>+</td>
<td>+</td>
<td>?</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Heller 1995</td>
<td>+</td>
<td>+</td>
<td>?</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Maltson 1985</td>
<td>?</td>
<td>?</td>
<td>+</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Ogunrin 2005</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>
Allocation

(1) Trials for which individual participant data (IPD) were provided

Three trials reported adequate methods of randomisation and allocation concealment; two trials used permuted blocks to generate a random list and concealed allocation by using sealed opaque envelopes (De Silva 1996; Heller 1995), and one trial used number tables to generate a random list and concealed allocation by allocating the randomised drug on a different site from where participants were randomised (Ogunrin 2005). One trial reported only that participants were randomised with stratification for seizure type (Mattson 1985); no further information was provided in the study publication or from the authors about the methods of generating the random list and concealment of allocation.

(2) Trials for which no IPD were available

One trial reported an adequate method of randomisation: random-number tables (Cereghino 1974), but no details were provided on concealment of allocation. Two trials reported inadequate methods of randomisation and allocation concealment; Forsythe 1991 reported a method of quota allocation and did not report how allocation was concealed, and Callaghan 1985 reported a method of randomisation and allocation concealment based on two Latin squares which seems to take into account the drug preference of participants (the "drug of first preference" was selected from the randomisation list on a sequential basis). The remaining five trials (Czapinski 1997; Miura 1993; Pulliainen 1994; Ramsay 1983; Ravi Sudhir 1995) reported that the participants were "randomised" or "randomly allocated" etc., but did not provide information of the method of generation of the random list or of allocation concealment.

Blinding

(1) Trials for which IPD were provided

One trial double-blinded participants and personnel using an additional blank tablet (Mattson 1985), but it is unclear if the outcome assessor was blinded in this trial. One trial blinded participants and the outcome assessors who performed cognitive testing, but a research assistant recruiting participants and providing counselling on medication adherence was not blinded (Ogunrin 2005). Two trials were unblinded for “practical and ethical reasons” (De Silva 1996; Heller 1995), but it is unclear whether the outcomes of these trials were influenced by the lack of masking.

(2) Trials for which no IPD were available

One trial double-blinded participants and personnel using an additional blank tablet (Ramsay 1983), but it is unclear if the outcome assessor was blinded in this trial. Two trials single-blinded the outcome assessor who performed cognitive testing; in one of these trials (Forsythe 1991) the participants and personnel were unblinded, and in the other (Pulliainen 1994), it was unclear if the participants and personnel were blinded or not. The remaining five trials (Callaghan 1985; Cereghino 1974; Czapinski 1997; Miura 1993; Ravi Sudhir 1995) did not provide any information on masking of participants, personnel or outcome assessors.

Incomplete outcome data

(1) Trials for which IPD were provided

In theory, a review using IPD should overcome issues of attrition bias, as unpublished data can be provided, unpublished outcomes calculated and all randomised participants can be analysed by an intention-to-treat approach. All four trials (De Silva 1996; Heller 1995; Mattson 1985; Ogunrin 2005) provided IPD for all randomised individuals and reported the extent of follow-up for each individual. We queried any missing data with the original study authors. From the information provided by the authors, we deemed the small amount of missing data (Included studies) to be missing at random and that they did not have an effect on our analysis.

(2) Trials for which no IPD were available

Three trials reported attrition rates and analysed all randomised participants using an intention-to-treat approach (Callaghan 1985; Forsythe 1991; Miura 1993). Two trials reported attrition rates, but it was unclear if all participants were analysed (Cereghino 1974; Czapinski 1997). Three studies excluded between 20% and 35% of participants from the final analysis for “non-compliance,” loss to follow-up or uncontrolled seizures, and included only those who completed the analysis. This approach is not intention-to-treat, so we deemed these three studies to be at high risk of bias (Pulliainen 1994; Ramsay 1983; Ravi Sudhir 1995).

Selective reporting

We requested study protocols in all IPD requests, but protocols were not available for any of the 12 included trials, so we made a judgement of the risk of bias based on the information included in the publications, or from the IPD we received (see Characteristics of included studies for more information).
Trials for which IPD were provided

In theory, a review using IPD should overcome issues of reporting biases, as unpublished data can be provided and unpublished outcomes calculated. We acquired sufficient IPD to calculate the four outcomes ('Time to withdrawal of allocated treatment', 'Time to six-month remission', 'Time to 12-month remission' and 'Time to first seizure') for three of the four trials (De Silva 1996; Heller 1995; Mattson 1985). The study duration of Ogunrin 2005 was 12 weeks and all randomised participants completed the study without withdrawing, so we could only calculate 'Time to first seizure' for this study.

Trials for which no IPD were available

Seizure outcomes or adverse events, or both, were fully reported in four trials (Callaghan 1985; Cereghino 1974; Miura 1993; Ramsay 1983). Two trials reported cognitive outcomes and adverse events, but no seizure outcomes (Forsythe 1991; Pulliainen 1994), and one trial reported cognitive outcomes only, but no adverse events or seizure outcomes (Ravi Sudhir 1995); however, as no protocols were available for these three trials, we do not know whether seizure outcomes or recording of adverse events, or both, were planned a priori. One trial was in abstract form only and did not provide sufficient information to assess selective reporting bias (Czapinski 1997).

Other potential sources of bias

We detected another source of bias in one of the included studies which has a cross-over design (Cereghino 1974). Such a design is unlikely to be appropriate for monotherapy treatment, due to carry-over effects from one treatment period into another (participants were also treated during washout periods with their "regular medication"), and such a design does not allow long-term outcomes such as the time-to-event outcomes of interest to us in this review. For future updates of this review we will exclude studies of a cross-over design.

Effects of interventions

See: Summary of findings for the main comparison Summary of findings - Time to withdrawal of allocated treatment; Summary of findings 2 Summary of findings - Time to 12- and 6-month remission of seizures; Summary of findings 3 Summary of findings - Time to first seizure after randomisation

A summary of the outcomes reported in trials for which no IPD were available are reported in Table 1. Details regarding the number of individuals (with IPD) contributing to each analysis are given in Table 2 and results are summarised in Summary of findings for the main comparison for our primary outcome 'Time to withdrawal of allocated treatment', Summary of findings 2 for the secondary outcomes 'Time to six- and 12-month remission' and Summary of findings 3 for the secondary outcome 'Time to first seizure'. Survival curve plots (cumulative incidence) are shown in Figure 4; Figure 5; Figure 6; Figure 7; Figure 8; Figure 9; Figure 10 and Figure 11. We produced all cumulative incidence plots in Stata software version 11.2 (Stata 2009), using data from all trials providing IPD combined. We would have liked to adjust for individual trials in survival curve plots but we do not know of any software which allows for this; we hope that such software may have been developed for future updates of this review.
Figure 4. Time to withdrawal of allocated treatment

Cumulative Incidence Plot by drug
Time to Withdrawal of Allocated Treatment

Number At Risk
CBZ  303  139  76  41  25  16  9  6  4  0
PHT  316  158  86  40  15  8  6  4  3  0

Proportion withdrawing from treatment
0.00  0.25  0.50  0.75  1.00
0  500  1000  1500  2000  2500  3000  3500  4000  4500
Time (days)

CBZ  PHT
Figure 5. Time to withdrawal of allocated treatment, stratified by epilepsy type
Figure 6. Time to 12 month remission

Cumulative Incidence Plot by drug
Time to 12 month remission

Proportion achieving remission

Time (days)

Number At Risk

<table>
<thead>
<tr>
<th></th>
<th>CBZ</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>259</td>
<td>75</td>
<td>25</td>
<td>15</td>
<td>11</td>
<td>10</td>
<td>5</td>
<td>2</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td>PHT</td>
<td>277</td>
<td>87</td>
<td>29</td>
<td>17</td>
<td>11</td>
<td>10</td>
<td>6</td>
<td>4</td>
<td>1</td>
<td>0</td>
</tr>
</tbody>
</table>

Figure 6. Time to 12 month remission
Figure 7. Time to 12 month remission, stratified by epilepsy type

Cumulative Incidence Plot by drug and epilepsy type
Time to 12 month remission

Proportion achieving remission

0.00 0.25 0.50 0.75 1.00

0 500 1000 1500 2000 2500 3000 3500 4000 4500

Time (days)

Number At Risk

<table>
<thead>
<tr>
<th></th>
<th>CBZ/G</th>
<th>CBZ/P</th>
<th>PHT/G</th>
<th>PHT/P</th>
</tr>
</thead>
<tbody>
<tr>
<td>At Risk</td>
<td>62</td>
<td>197</td>
<td>59</td>
<td>218</td>
</tr>
<tr>
<td>CBZ/G</td>
<td>23</td>
<td>52</td>
<td>24</td>
<td>63</td>
</tr>
<tr>
<td>CBZ/P</td>
<td>9</td>
<td>16</td>
<td>11</td>
<td>18</td>
</tr>
<tr>
<td>PHT/G</td>
<td>5</td>
<td>10</td>
<td>5</td>
<td>12</td>
</tr>
<tr>
<td>PHT/P</td>
<td>4</td>
<td>7</td>
<td>2</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>6</td>
<td>1</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
Figure 8. Time to 6 month remission

Cumulative Incidence Plot by drug

Time to 6 month remission

Proportion achieving remission

Number At Risk

Time (days)

CBZ 258 35 10 8 6 4 2 1 1 0
PHT 277 31 17 12 9 9 6 3 1 0
Figure 9. Time to 6 month remission, stratified by epilepsy type

Cumulative Incidence Plot by drug and epilepsy type

Time to 6 month remission

Proportion achieving remission

0.00 0.25 0.50 0.75 1.00

0 500 1000 1500 2000 2500 3000 3500 4000 4500

Time (days)

Number At Risk

CBZ/G 62 10 4 3 2 2 2 1 1 0
CBZ/P 196 25 6 5 4 2 0 0 0 0
PHT/G 59 8 5 3 1 1 0 0 0 0
PHT/P 218 23 12 9 8 8 5 3 1 0

CBZ/Generalized
CBZ/Partial
PHT/Generalised
PHT/Partial
Figure 10. Time to first seizure

Cumulative Incidence Plot by drug
Time to first seizure

Proportion with seizure recurrence

0.00 0.25 0.50 0.75 1.00

Time (days)

Number At Risk
CBZ 269 55 24 13 8 5 3 1 1 0
PHT 285 56 28 22 13 10 9 6 2 1
Figure 11. Time to first seizure, stratified by epilepsy type

Cumulative Incidence Plot by drug and epilepsy type

Time to first seizure

Proportion with seizure recurrence

0.00 0.25 0.50 0.75 1.00

Cumulative Incidence

0 500 1000 1500 2000 2500 3000 3500 4000 4500

Time (days)

Number At Risk

CBZ/G 76 23 12 9 6 5 3 1 1 0
CBZ/P 193 32 12 4 2 0 0 0 0 0
PHT/G 74 25 16 12 10 8 7 4 1 0
PHT/P 211 31 12 10 3 2 2 1 1

All hazard ratios (HRs) presented below are calculated by generic inverse variance fixed-effect meta-analysis unless otherwise stated.

Time to withdrawal of allocated treatment

For this outcome, a HR greater than one indicates a clinical advantage for carbamazepine.

Time to withdrawal of allocated treatment and reason for withdrawal were available for 546 participants from three of the four trials providing IPD (99% of 558 participants from De Silva 1996, Heller 1995 and Mattson 1985 (see Included studies), and 45.8% of the 1192 participants from the 12 included studies). Although two participants withdrew from allocated treatment (one in each group) in De Silva 1996, a reason for withdrawal was not available and could not be determined from the case notes. Similarly in Heller 1995, for one participant taking carbamazepine, the reason for withdrawal was not available and could not be determined from the case notes. Also in Heller 1995, two participants (both on phenytoin) had reasons for treatment withdrawal recorded but no date of withdrawal. We have not included the five participants with missing reasons for withdrawal or withdrawal dates from the two trials in analysis of time to withdrawal of allocated treatment. Sufficient IPD were available in the published report for a further 43 participants from one trial (Forsythe 1991). Therefore, 589 participants from four trials were available for the analysis of this outcome (see Table 2).

350 participants prematurely withdrew from treatment (59%): 172 out of 290 participants randomised to carbamazepine (59%) and 178 out of 299 participants randomised to phenytoin (60%). See Table 3 for reasons for premature termination of allocated treatment (by treatment) and how we classified these withdrawals in analysis. We deemed 210 participants (36%) to have withdrawn for reasons related to the study drug, 103 (36%) on carbamazepine and 107 (36%) on phenytoin, and we classified these withdrawals as ‘events’ in analysis. We classified the other 140 withdrawals as not related to the study drug and censored these participants in analysis, in addition to those who completed the study without withdrawing.

The overall pooled HR (for 589 participants in four trials) was 0.99 (95% confidence interval (CI) 0.75 to 1.30, P = 0.92), indicating no advantage for either drug. There was no evidence of statistical heterogeneity between trials (Chi² = 2.73, degrees of freedom (df) = 3, P = 0.44, I²= 0%, see Analysis 1.1). The proportional hazards
assumption of the Cox model was satisfied for all trials.
Phenytoin is no longer considered as a first-line treatment in much
of the USA and Europe, due to concerns around adverse events (see
Description of the intervention). Table 3 shows that 26 out of 172
participants (15%) who withdrew from carbamazepine and 12 out
of 178 participants (7%) who withdrew from phenytoin withdrew
from the study due to adverse events; in other words, statistically
significantly more participants withdrew from carbamazepine than
from phenytoin due to adverse events in four studies conducted
in the USA and Europe (P = 0.012).
Withdrawal data for 43 participants extracted from Forsythe 1991
did not distinguish between epilepsy type (partial onset or gen-
eralised onset) and therefore could not be included in the meta-
analysis stratified by epilepsy type.
The overall pooled HR (adjusted by epilepsy type for 546 partic-
Participants in three trials) was 1.04 (95% CI 0.78 to 1.39, P = 0.79),
again indicating no clear advantage for either drug, and there was
no evidence of statistical heterogeneity between trials (Chi² = 5.86,
df = 4, P = 0.21, I² = 32%, see Analysis 1.2). This result is similar to
the unadjusted pooled HR (Analysis 1.1) and conclusions remain
unchanged following the exclusion of 43 individuals (Forsythe
1991) in the stratified analysis.
For participants with partial onset seizures (n = 428, three tri-
als), the pooled HR was 1.18 (95% CI 0.87 to 1.60, P = 0.30), indicating an advantage for carbamazepine, which is not statisti-
cally significant. For participants with generalised onset seizures
(n = 118, two trials), the pooled HR was 0.42 (95% CI 0.18 to
0.96, P = 0.04), indicating a statistically significant advantage for
phenytoin. We found a statistically significant interaction between
seizure type (generalised versus partial onset) and treatment effect
(Chi² = 5.18, df = 1, P = 0.02, I² = 80.7%).
We conducted a sensitivity analysis to examine the impact of po-
tential seizure miscategorisation on results for the 29 participants
aged 30 years or older with new-onset generalised seizures in Heller
1995 (see Sensitivity analysis). Following reclassification, for the
remaining participants with generalised onset seizures (89) the
pooled HR was 0.51 (95% CI 0.21 to 1.24, P = 0.14), which
still indicates an advantage for phenytoin, but this advantage is no
longer statistically significant. Reclassifying these 29 participants
as having new-onset partial seizures, the pooled HR for 517 partic-
Participants is 1.11 (95% CI 0.82 to 1.50, P = 0.50), indicating a
slight advantage for carbamazepine, which is not statistically sig-
nificant. Following reclassification, the interaction between seizure
type (generalised versus partial onset) and treatment effect is no
longer statistically significant (Chi² = 2.16, df = 1, P = 0.10, I²
= 62.3%). Results were similar when the 29 participants were
reclassified as uncertain seizure type (see Table 4).
Given that subgroup sizes are unbalanced (118 with generalised
seizures and 428 with partial seizures (as classified by the studies))
and that results may be confounded by misclassification of seizure
type in up to 29 participants, we cannot draw any firm conclusions
about an association between treatment and seizure type (i.e. that
participants with partial seizures are less likely to withdraw from
phenytoin and participants with generalised seizures are less likely
to withdraw from carbamazepine). We require more evidence, par-
ticularly from individuals with correctly classified generalised on-
set seizures to inform this analysis.
We judged evidence for "Time to withdrawal of allocated treat-
ment" to be of moderate quality according to GRADE criteria,
due to the potential impact of misclassification of seizure type on
the results (Summary of findings for the main comparison).

Time to achieve 12-month remission
For this outcome, a HR greater than one indicates a clinical ad-

antage for phenytoin.
Data for 551 participants (99% of 558 randomised participants
from De Silva 1996, Heller 1995 and Mattson 1985 (see Included
studies) and 45.8% of the 1192 participants from the 12 included
studies) from three out of four trials providing IPD were available
for the analysis of this outcome. Individuals were followed up for a
maximum of 12 weeks in Ogurin 2005, so it could not contribute
to this outcome.
Two hundred and eighty-nine out of 551 participants (52%)
achieved 12-month remission: 155 out of 282 (55%) on pheny-
toin and 134 out of 269 (50%) on carbamazepine. The overall
pooled HR (for 551 participants, three trials) was 0.99 (95% CI
0.79 to 1.25, P = 0.95), suggesting no advantage for either drug.
There was no evidence of statistical heterogeneity between trials
(Chi² = 1.49, df = 2, P = 0.47, I² = 0%, see Analysis 1.3).
Substantial statistical heterogeneity was present between the trials
for generalised onset seizures (I² = 73%, P = 0.06), so we calculated
HRs using the random-effects model. For participants with partial
onset seizures (n = 430, three trials), the pooled HR was 0.94 (95% CI
0.71 to 1.25, P = 0.68, random-effects), indicating no clear
advantage for either drug. For participants with generalised onset
seizures (n = 121, two trials), the pooled HR was 1.17 (95% CI
0.53 to 2.57, P = 0.70, random-effects), indicating an advantage
for phenytoin, which is not statistically significant. Overall, the
pooled HR (adjusted for seizure type for 551 participants, three
trials) was 1.01 (95% CI 0.78 to 1.31, P = 0.93, random-effects),
suggesting no clear advantage for either drug (see Analysis 1.4).
The test for interaction between seizure type (generalised versus
partial onset) and treatment effect was not significant (Chi² = 0.25,
df = 1, P = 0.62, I² = 0%).
Following reclassification of the 29 participants aged 30 years
or older with new-onset generalised seizures in Heller 1995 (see
Sensitivity analysis), the pooled HR for 92 participants with gen-
eralised onset seizures was 1.44 (95% CI 0.90 to 2.31, P = 0.32,
I² = 0%, calculated with fixed-effect model), showing that all of
the heterogeneity in Analysis 1.4 is explained by misclassification
of participants with generalised onset seizures. The pooled esti-
mate for individuals with partial onset seizures and the overall
estimate for all participants stratified by seizure type were similar to

Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
In De Silva 1996, there is an indication that the proportional hazards assumption may be violated (see Data synthesis); the P value of time-varying covariate is 0.051 and visual inspection of the cumulative incidence plot (Figure 12) shows crossing of the curves at around 2500 days. In other words, up to 2500 days, participants on phenytoin seem to be achieving 12-month remission quicker than those on carbamazepine, but this changes after 2500 days; however, participant numbers are small (15 participants at risk out of 108 randomised), so small changes may be magnified at this time.

As a sensitivity analysis, we fitted a piecewise Cox regression model to investigate any change in treatment effect over time, assuming proportional hazards within each interval. From the visual inspection of Figure 12, the follow-up period of De Silva 1996 is split into two intervals: 0 to 2500 days and over 2500 days (maximum follow-up was 4163 days). We can estimate separate HRs for each interval as follows:
- For the interval 0 to 2500 days (88 events in 108 participants at risk) the HR is 1.29 (95% CI 0.84 to 1.96, P = 0.23), suggesting an advantage for phenytoin, which is not statistically significant.
For the interval over 2500 days (five events in 15 participants at risk) the HR is 0.63 (95% CI 0.25 to 1.57, P = 0.32), suggesting an advantage for carbamazepine, which is not statistically significant.

These results suggest some indication of a change in treatment effect over time, with an advantage for phenytoin earlier on in the study, changing to an advantage for carbamazepine later in the study. However, CIs of estimates are wide, particularly for the HR after 2500 days due to small numbers of events and participants at risk, so we do not have statistically significant evidence to support the hypothesis of a change in treatment effect over time for De Silva 1996, and conclude that the change of direction in effect at around 2500 days is likely to be due to small participant numbers after this time.

We judged the evidence for 'Time to 12-month remission' to be of low to moderate quality according to GRADE criteria, due to the potential impact of misclassification of seizure type on the results and heterogeneity between studies (Summary of findings 2).

### Time to achieve six-month remission

For this outcome, a HR greater than one indicates a clinical advantage for phenytoin.

Data for 551 participants (99% of 558 randomised participants from De Silva 1996, Heller 1995 and Matsson 1985 (see Included studies) and 45.8% of the 1192 participants from the 12 included studies) from three out of four trials providing IPD were available for the analysis of this outcome. Individuals were followed up for a maximum of 12 weeks in Ogunrin 2005, so it could not contribute to this outcome.

Three hundred and thirty-eight out of 551 participants (61%) achieved six-month remission: 179 out of 282 (63%) on phenytoin and 159 out of 269 (59%) on carbamazepine. The overall pooled HR (for 551 participants, three trials) was 1.08 (95% CI 0.87 to 1.34, P = 0.46), suggesting no clear advantage for either drug. There was no evidence of statistical heterogeneity between trials (Chi$^2 = 0.35$, df = 2, P = 0.84, I$^2 = 0%$, see Analysis 1.5).

For the participants with partial onset seizures (n = 430, three trials), the pooled HR was 1.02 (95% CI 0.79 to 1.33, P = 0.85), indicating no clear advantage for either drug. For the participants with generalised onset seizures (n = 121, two trials), the pooled HR was 1.30 (95% CI 0.89 to 1.92, P = 0.18), indicating an advantage for phenytoin, which is not statistically significant. Less statistical heterogeneity was present between the trials for generalised onset seizures compared to the analysis of time to 12-month remission (I$^2 = 39\%$, P = 0.20), so we present HRs from a fixed-effect model. Overall, the pooled HR (adjusted for epilepsy type for 551 participants, three trials) was 1.11 (95% CI 0.89 to 1.37, P = 0.36, three trials), suggesting a slight advantage for phenytoin, which is not statistically significant. The test for interaction between seizure type (generalised versus partial onset) and treatment effect was not significant (Chi$^2 = 1.03$, df = 1, P = 0.31, I$^2 = 3.4\%$, see Analysis 1.6).

Following reclassification of the 29 participants aged 30 years or older with new-onset generalised seizures in Heller 1995 (see Sensitivity analysis), the pooled HR for 92 participants with generalised onset seizures was 1.69 (95% CI 1.07 to 2.27, P = 0.02, I$^2 = 0\%$), showing a larger and statistically significant advantage for phenytoin. Reclassifying these 29 participants as having new-onset partial seizures, the pooled HR for 517 participants is 1.02 (95% CI 0.80 to 1.31), similar to Analysis 1.6, indicating no clear advantage for either drug. Following reclassification, the test for interaction between seizure type (generalised versus partial onset) and treatment effect was borderline statistically significant (Chi$^2 = 3.63$, df = 1, P = 0.06, I$^2 = 72.5\%$). Results were similar when the 29 participants were reclassified as uncertain seizure type (see Table 4).

However, as in the analysis of our primary outcome 'Time to withdrawal of allocated treatment', as subgroup sizes are unbalanced (118 with generalised seizures and 428 with partial seizures, as classified by the studies) and as results may be confounded by misclassification of seizure type in up to 29 participants, we cannot draw any firm conclusions about an association between treatment and seizure type (i.e. that participants achieve six-month remission quicker on phenytoin than on carbamazepine). Again, we require more evidence, particularly from individuals with correctly classified generalised onset seizures to inform this analysis.

In De Silva 1996, there is an indication that the proportional hazards assumption may be violated (see Data synthesis); the P value of time-varying covariate is 0.066 and visual inspection of the cumulative incidence plot (Figure 13) shows crossing of the curves at several points at around 1000 days, 1750 days and 3500 days, suggesting several changes in treatment effect over time. As in the sensitivity analysis of De Silva 1996 in 'Time to 12-month remission', after 1000 days participant numbers are small (18 participants at risk out of 108 randomised), so small changes may be magnified in the later stages of study follow-up.
As a sensitivity analysis, we fitted a piecewise Cox regression model to investigate any change in treatment effect over time, assuming proportional hazards within each interval. From the visual inspection of Figure 13, the follow-up period of De Silva 1996 is split into three intervals; 0 to 1000 days, 1000 to 1750 days, and over 1750 days (maximum follow-up is 4163 days). We did not consider an interval of 3500 days to the end of the study, due to very small participant numbers at this time (three participants at risk). We can estimate separate HRs for each interval as follows:

- For the interval 0 to 1000 days (87 events in 108 participants at risk) the HR is 1.18 (95% CI 0.77 to 1.80, \( P = 0.44 \)), suggesting an advantage for phenytoin, which is not statistically significant.
- For the interval 1000 to 1750 days (three events in 18 participants at risk) the HR is 1.26 (95% CI 0.37 to 4.18, \( P = 0.71 \)), again suggesting an advantage for phenytoin, which is not statistically significant.
- For intervals over 1750 days (five events in 14 participants at risk) the HR is 0.76 (95% CI 0.41 to 1.39), suggesting an advantage for carbamazepine, which is not statistically significant.

As above, these results suggest some indication of a change in treatment effect over time, with an advantage for phenytoin earlier on in the study, changing to an advantage for carbamazepine later in the study. However, CIs of estimates are again wide, due to small participant numbers in the later two intervals, so we do not have statistically significant evidence to support the hypothesis of a change in treatment effect over time for De Silva 1996, and conclude that the apparent changes of direction in effect at later stages of the study are likely to be due to small participant numbers.

We judged evidence for 'Time to six-month remission' to be of moderate quality according to GRADE criteria, due to the potential impact of misclassification of seizure type on the results (Summary of findings 2).

**Time to first seizure post-randomisation**

For this outcome, a HR greater than one indicates a clinical advantage for carbamazepine.

Data for 582 participants (99% of 558 randomised participants from De Silva 1996, Heller 1995 and Mattson 1985 (see Included studies), 100% from Ogunrin 2005, and 49% of the 1192 partic-
Participants from the 12 included studies) from all four trials providing IPD were available for the analysis of this outcome. Three hundred and eighty-three out of 582 participants (66%) experienced a recurrence of seizures: 192 out of 297 (64%) on phenytoin and 191 out of 285 on carbamazepine (67%). The overall pooled HR (for 582 participants, four trials) was 0.88 (95% CI 0.72 to 1.08, P = 0.21), suggesting a slight advantage for phenytoin, which is not statistically significant. There was little evidence of statistical heterogeneity between trials (Chi² = 4.53, df = 3, P = 0.21, I² = 34%, see Analysis 1.7).

For the participants with partial onset seizures (n = 432, four trials), the pooled HR was 0.86 (95% CI 0.68 to 1.08, P = 0.20), indicating a slight advantage for phenytoin, which is not statistically significant. For the participants with generalised onset seizures (n = 150, three trials), the pooled HR was 0.84 (95% CI 0.57 to 1.24, P = 0.38), again indicating a slight advantage for phenytoin, which is not statistically significant. Again, there was some statistical heterogeneity between trials for generalised onset seizures (I² = 45%, P = 0.16). Overall, the pooled HR (adjusted for epilepsy type for 582 participants, four trials) was 0.85 (95% CI 0.70 to 1.04, P = 0.38), suggesting a slight advantage for phenytoin, which is not statistically significant. The test for interaction between seizure type (generalised versus partial onset) and treatment effect was not significant (Chi² = 0.01, df = 1, P = 0.93, I² = 0%, see Analysis 1.8).

Following reclassification of the 48 participants aged 30 years or older with new-onset generalised seizures in Heller 1995 and Ogunrin 2005 (see Sensitivity analysis), results were very similar and conclusions were unchanged (see Table 4). Unlike in analysis of ‘Time to 12-month remission’, heterogeneity for participants with generalised onset seizures in Analysis 1.8 is barely reduced following reclassification of seizure type (I² is reduced from 45% to 42% following reclassification).

Following visual inspection of the forest plot in Analysis 1.8 (generalised epilepsy type), there is a difference in the direction of effects of the three studies, with De Silva 1996 and Ogunrin 2005 showing an advantage for phenytoin, which is not statistically significant, and Heller 1995 showing a slight advantage for carbamazepine, which is not statistically significant).

From correspondence with the study authors, we know that De Silva 1996 and Heller 1995 were conducted under the same protocol and therefore trial characteristics should be homogeneous; the only difference between the two studies is within the age groups recruited (De Silva 1996 recruited children only and Heller 1995 recruited adults only). We therefore performed a further subgroup analysis by adult versus paediatric studies (Ogunrin 2005 also recruited adults only). For 101 adults with generalised onset seizures, the pooled HR was 1.02 (95% CI 0.62 to 1.68, P = 0.94), indicating no clear advantage for either drug, and for 49 children with generalised onset seizures in De Silva 1996 the HR was 0.63 (95% CI 0.34 to 1.16, P = 0.14), indicating an advantage for phenytoin, which is not statistically significant.

The test for interaction between age groups recruited (adults versus children) and treatment effect was not significant (Chi² = 1.45, df = 1, P = 0.23, I² = 30.9%). However, participant numbers with generalised onset seizures are quite limited in this review, so we may not have had the power to detect a difference between age groups.

In Ogunrin 2005 there is an indication that the proportional hazards assumption may be violated (see Data synthesis); the P value of time-varying covariate is 0.02 and visual inspection of the cumulative incidence plot (Figure 14) shows clear crossing of the curves at around 10 days. In other words, up to 10 days, more participants seem to be having seizure recurrence on phenytoin, but this changes to those on carbamazepine after 10 days.
As a sensitivity analysis, we fitted a piecewise Cox regression model to investigate any change in treatment effect over time, assuming proportional hazards within each interval. From the visual inspection of Figure 14, the follow-up period of Ogunrin 2005 is split into two intervals; 0 to 10 days and over 10 days (maximum follow-up is 84 days). We can estimate separate HRs for each interval as follows:

- For the interval 0 to 10 days (13 events in 37 participants at risk) the HR is 1.49 (95% CI 0.45 to 4.88, P = 0.51), suggesting an advantage for carbamazepine, which is not statistically significant.
- For intervals over 10 days (eight events in 24 participants at risk) the HR is 32 (95% CI 0.11 to 0.91, P = 0.03), suggesting a large statistically significant advantage for phenytoin. Visual inspection of Figure 14 also shows a clear advantage for phenytoin after 10 days.

These results suggest some indication of a change in treatment effect over time, with a slight early advantage for carbamazepine, changing to a large statistically significant advantage for phenytoin later in the study, and support the hypothesis of a change in treatment effect over time for Ogunrin 2005. Ogunrin 2005 is by far the shortest of the studies for which we have IPD (maximum follow-up was 84 days in Ogunrin 2005 compared to maximum follow-up of 3995 days in Heller 1995, 4589 days in De Silva 1996 and 1838 days in Mattson 1985), and we did not find statistically significant evidence of a difference between carbamazepine and phenytoin for ‘Time to first seizure after randomisation’ in any of the three studies with a longer duration (see Analysis 1.7). The apparent large advantage for phenytoin from 10 to 84 days in Ogunrin 2005, may therefore have reduced in size or even changed direction to favour carbamazepine if this study had continued for a longer duration.

We judged evidence for ‘Time to first seizure after randomisation’ to be of low to moderate quality according to GRADE criteria, due to the potential impact of misclassification of seizure type on the results and imprecision of the effect sizes (Summary of findings 3).

Adverse events
We extracted all reported information related to adverse events from the study publications. Miura 1993 and Ravi Sudhir 1995
did not report any information on adverse events and we are uncertain without access to protocols if these data were collected (see Selective reporting (reporting bias)). See Table 5 for details of all adverse event data provided in the other 10 studies included in this review. In summary, the adverse events reported by two or more studies in this review are as follows:

For carbamazepine

- Gastrointestinal side effects including abdominal pain, nausea and vomiting: (Cereghino 1974; Forsythe 1991; Mattson 1985; Ramsay 1983).
- Decreased libido, or impotence, or both: (Mattson 1985; Ramsay 1983).
- Motor disturbance (including ataxia, incoordination, nystagmus, tremor, slowing of mental function, inattention, psychomotor retardation): (Forsythe 1991; Mattson 1985; Ogunrin 2005; Ramsay 1983).
- Dysmorphic and idiosyncratic side effects (gum hypertrophy, hirsutism, acne, other skin problems): (Mattson 1985; Pulliainen 1994; Ramsay 1983).
- Cognitive side effects and impairments, including depression and memory problems: (Heller 1995; Ogunrin 2005; Pulliainen 1994; Ramsay 1983).

For phenytoin

- Gastrointestinal side effects including abdominal pain, nausea and vomiting: (Cereghino 1974; Mattson 1985; Ramsay 1983).
- Drowsiness/tiredness/fatigue/sedation: (De Silva 1996; Pulliainen 1994; Ramsay 1983).
- Decreased libido, or impotence, or both: (Mattson 1985; Ramsay 1983).
- Motor disturbance (including ataxia, incoordination, nystagmus, tremor, slowing of mental function, inattention, psychomotor retardation): (Callaghan 1985; Mattson 1985; Ogunrin 2005; Ramsay 1983).
- Dysmorphic and idiosyncratic side effects (gum hypertrophy, hirsutism, acne, other skin problems): (Callaghan 1985; De Silva 1996; Mattson 1985; Ramsay 1983).
- Cognitive side effects and impairments, including depression and memory problems: (Forsythe 1991; Ogunrin 2005; Ramsay 1983).

Because of the differences in methods of reporting adverse event data across the studies (see Table 5), it is difficult to summarise the 'most common' adverse events overall across the 12 studies, or to deduce whether carbamazepine or phenytoin are most associated with specific adverse events. Adverse event data for individuals were not included in the original IPD requests for earlier versions of this review, but will be sought in all future IPD requests.
## ADDITIONAL SUMMARY OF FINDINGS

### Carbamazepine compared with phenytoin for epilepsy

**Patient or population:** adults and children with new-onset partial or generalised epilepsy  
**Settings:** outpatients  
**Intervention:** carbamazepine  
**Comparison:** phenytoin

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No. of Participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assumed risk</td>
<td>Corresponding risk</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Phenytoin</td>
<td>Carbamazepine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to 12-month remission - stratified by epilepsy type</td>
<td>55 per 100</td>
<td>55 per 100 (46 to 65)</td>
<td>HR 1.01 (0.78 to 1.31)</td>
<td>551 (3 studies)</td>
<td>⊕⊕⊕ moderate^{2,3}</td>
</tr>
<tr>
<td></td>
<td>Range of follow-up (all participants): 0 days to 4222 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to 12-month remission - partial epilepsy</td>
<td>47 per 100</td>
<td>45 per 100 (36 to 55)</td>
<td>HR 0.94 (0.71 to 1.25)</td>
<td>430 (3 studies)</td>
<td>⊕⊕⊕ moderate^{2,3}</td>
</tr>
<tr>
<td></td>
<td>Range of follow-up (all participants): 0 days to 4222 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time to 12-month remission - generalised epilepsy</td>
<td>85 per 100</td>
<td>88 per 100 (63 to 99)</td>
<td>HR 1.17^{4} (0.53 to 2.57)</td>
<td>121 (2 studies)</td>
<td>⊕⊕⊕ low^{2,3,4}</td>
</tr>
<tr>
<td></td>
<td>Range of follow-up (all participants): 7 days to 4163 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Time to 6-month remission</td>
<td>63 per 100</td>
<td>67 per 100 (59 to 75)</td>
<td>HR 1.11 (0.89 to 1.37)</td>
<td>551 (3 studies)</td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
</tr>
<tr>
<td>- stratified by epilepsy type</td>
<td>Range of follow-up (all participants): 0 days to 4222 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time to 6-month remission</th>
<th>56 per 100</th>
<th>56 per 100 (47 to 66)</th>
<th>HR 1.02 (0.79 to 1.33)</th>
<th>430 (3 studies)</th>
<th>⚫⚫⚫ moderate²,³</th>
<th>HR &gt;1 indicates a clinical advantage for phenytoin</th>
</tr>
</thead>
<tbody>
<tr>
<td>- partial epilepsy</td>
<td>Range of follow-up (all participants): 0 days to 4222 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time to 6-month remission</th>
<th>93 per 100</th>
<th>97 per 100 (91 to 99)</th>
<th>HR 1.30 (0.89 to 1.92)</th>
<th>121 (2 studies)</th>
<th>⚫⚫⚫ moderate²,³</th>
<th>HR &gt;1 indicates a clinical advantage for phenytoin</th>
</tr>
</thead>
<tbody>
<tr>
<td>- generalised epilepsy</td>
<td>Range of follow-up (all participants): 7 days to 4163 days</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The assumed risk is calculated as the event rate in the Phenytoin treatment group. The corresponding risk in the carbamazepine treatment group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

The corresponding risk is calculated as the assumed risk x the relative risk (RR) of the intervention where RR = (1 - exp(HR x ln(1 - assumed risk))) / assumed risk

| CI: Confidence interval; HR: Hazard Ratio; exp: exponential |

GRADE Working Group grades of evidence

**High quality:** Further research is very unlikely to change our confidence in the estimate of effect.

**Moderate quality:** Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.

**Low quality:** Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.

**Very low quality:** We are very uncertain about the estimate.

¹Pooled HR for all participants adjusted for seizure type.
Risk of bias unclear for one element of all of the three studies included in the analysis. De Silva 1996 and Heller 1995 are open-label and it is unclear whether the lack of masking impacted upon the results; and we do not know how allocation was concealed in Matsen 1995.

29 adults participants in Heller 1995 may have had their seizure type wrongly classified as generalised onset; sensitivity analyses show misclassification may have had an impact on results and conclusions regarding an association between treatment and seizure type.

Time to 12-month remission for 121 individuals with generalised seizures calculated with random-effects model due to heterogeneity between participants. This heterogeneity is likely to be due to misclassification of seizure type (see footnote 3).
### Carbamazepine compared with phenytoin for epilepsy

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Illustrative comparative risks* (95% CI)</th>
<th>Relative effect (95% CI)</th>
<th>No of Participants (studies)</th>
<th>Quality of the evidence (GRADE)</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phenytoin</strong></td>
<td><strong>Corresponding risk</strong></td>
<td><strong>Relative effect</strong></td>
<td><strong>Quality of the evidence</strong></td>
<td><strong>Comments</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Assumed risk</strong></td>
<td><strong>Carbamazepine</strong></td>
<td><strong>(95% CI)</strong></td>
<td><strong>(studies)</strong></td>
<td><strong>low</strong></td>
<td><strong>HR &gt; 1 indicates a clinical advantage for carbamazepine</strong></td>
</tr>
<tr>
<td>Time to first seizure - stratified by epilepsy type</td>
<td>Range of follow-up (all participants): 0 days to 4589 days</td>
<td>65 per 100</td>
<td>71 per 100 (63 to 77)</td>
<td>HR 0.85 (0.70 to 1.04)</td>
<td>582 (4 studies)</td>
</tr>
<tr>
<td>Time to first seizure - partial epilepsy</td>
<td>Range of follow-up (all participants): 0 days to 4589 days</td>
<td>63 per 100</td>
<td>68 per 100 (60 to 77)</td>
<td>HR 0.86 (0.68 to 1.08)</td>
<td>432 (4 studies)</td>
</tr>
<tr>
<td>Time to first seizure - generalised epilepsy</td>
<td>Range of follow-up (all participants): 2 days to 4070 days</td>
<td>69 per 100</td>
<td>75 per 100 (61 to 87)</td>
<td>HR 0.84 (0.57 to 1.24)</td>
<td>150 (3 studies)</td>
</tr>
</tbody>
</table>

---

Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
The basis for the **assumed risk** (e.g., the median control group risk across studies) is provided in footnotes. The assumed risk is calculated as the event rate in the Phenytoin treatment group. The corresponding risk in the carbamazepine treatment group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).

The corresponding risk is calculated as the assumed risk \( \times \) the relative risk (RR) of the intervention where

\[
RR = \frac{1 - \exp(HR \times \ln(1 - \text{assumed risk}))}{\text{assumed risk}}
\]

<table>
<thead>
<tr>
<th>CI: Confidence interval; HR: Hazard Ratio; exp: exponential</th>
</tr>
</thead>
</table>

**GRADE Working Group grades of evidence**

- **High quality**: Further research is very unlikely to change our confidence in the estimate of effect.
- **Moderate quality**: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
- **Low quality**: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
- **Very low quality**: We are very uncertain about the estimate.

---

1. Pooled HR for all participants adjusted for seizure type.
2. Risk of bias unclear for one element of all of the three studies included in the analysis. *De Silva 1996* and *Heller 1995* are open-label and it is unclear whether the lack of masking impacted upon the results; and we do not know how allocation was concealed in *Mattson 1985*.
3. 48 adult participants in *Heller 1995* and *Ogunrin 2005* may have had their seizure type wrongly classified as generalised onset; sensitivity analyses show misclassification is unlikely to have had an impact on results and conclusions.
4. *Ogunrin 2005* is a short study (12 weeks) and has a small sample size of 37 compared to the other three studies of duration 3 - 10 years and sample sizes of around 100 to 300 participants (*De Silva 1996*; *Heller 1995*; *Mattson 1985*). *Ogunrin 2005* is less precise with wide CIs, and there is evidence that the treatment effect in this study changes over time.
DISCUSSION

Summary of main results

The results of this review demonstrate a statistically significant advantage for phenytoin over carbamazepine for the 118 individuals with new-onset generalised tonic-clonic seizures for the primary global outcome 'Time to withdrawal of allocated treatment'; however, this result is likely to have been confounded by misclassification of seizure type for 29 individuals and when this misclassification is taken into account in sensitivity analysis, the advantage for phenytoin is no longer statistically significant. Results for 428 individuals with new-onset partial seizures suggest an advantage for carbamazepine, which is not statistically significant. Overall, for the 546 individuals contributing withdrawal data to this review, we found no statistically significant evidence for a difference between carbamazepine and phenytoin.

Results of this review also show that among 589 participants recruited in the USA and Europe, carbamazepine is around twice as likely to be withdrawn than phenytoin for adverse events, despite concerns about serious adverse events leading to the replacement of phenytoin with carbamazepine or lamotrigine as a first-line drug for partial onset seizures across much of the USA and Europe (NICE 2012). Our primary outcome is a measure of effectiveness influenced by both the relative efficacy of the two drugs and differences in tolerability and safety, so a difference in efficacy in one direction may be confounded by a difference in tolerability in the other. It may therefore not be surprising that any estimated differences are small, and the results of this review cannot exclude clinically important differences between the drugs and between seizure types. Furthermore, the largest study, contributing over 60% of participants to the analysis of our primary outcome, recruited participants with partial onset seizures only, so the subgroups of participants by seizure type are unbalanced in size (428 participants with partial seizures versus 118 with generalised seizures), resulting in less precise results and wide CIs for individuals with generalised onset seizures.

Similarly for the secondary outcomes 'Time to 12-month remission', 'Time to six-month remission', and 'Time to first seizure', we found no statistically significant differences between phenytoin and carbamazepine, for participants overall or by seizure type. However, subgroups of participants by seizure type are again unbalanced in size, and misclassification of seizure types may have confounded analyses. More evidence is needed, particularly from individuals with correctly classified generalised seizures, to inform all of the outcomes of this review.

For all outcomes in this review we would recommend caution in the interpretation of the results (see Overall completeness and applicability of evidence), and we would not recommend basing a choice between these two drugs on the results of this review alone.

Overall completeness and applicability of evidence

We believe our systematic electronic searches identified all relevant evidence for this review. We have gratefully received individual participant data (IPD) for 595 individuals (50% of individuals from all eligible trials) from the authors of four trials (De Silva 1996; Heller 1995; Mattson 1985; Ogunrin 2005), which included a comparison of phenytoin versus carbamazepine for the treatment of epilepsy. However, 574 individuals (48%) from seven relevant trials (Callaghan 1985; Cereghino 1974; Czapiński 1997; Miura 1993; Pulliainen 1994; Ramsay 1983; Ravi Sudhir 1995) could not be included in any analysis as IPD were not available and outcomes of interest were not reported in the published reports. Sufficient data for 23 individuals (2%) were published in one trial (Forsythe 1991) to contribute to analysis for the primary outcome 'Time to withdrawal of allocated treatment', but insufficient data were available to include these individuals in the analyses by seizure type and the analyses of other outcomes. Having to exclude data from half of eligible participants due to lack of IPD and insufficient reporting in study publications is likely to have impacted on the applicability of the evidence, but it is difficult to quantify exactly how large this impact was on the results of this review (see Potential biases in the review process).

Three trials contributing around 80% of the participant data to this review recruited adults only (Heller 1995; Mattson 1985; Ogunrin 2005); the remaining study was a paediatric trial (De Silva 1996). Also, the largest single trial contributing over half of the participant data to this review (Mattson 1985) recruited individuals with partial onset seizures only, so that only around 25% of participants included in this review were experiencing generalised onset seizures. Furthermore, there is evidence within this review to suggest that up to 30% of individuals with new-onset generalised seizures may have had their seizure type misclassified. For these reasons, the results of this review may not be fully generalisable to children or to individuals with generalised onset seizures, and more evidence is required from participants with generalised seizure types.

Quality of the evidence

The four trials for which IPD were available were generally at low risk of bias (see Figure 3). Three of the trials contributing around half of the participant data to this review described adequate methods of randomisation and allocation concealment (De Silva 1996; Heller 1995; Ogunrin 2005), but the largest single trial contributing 54% of participant data (Mattson 1985) did not describe the method of randomisation and allocation concealment used, and this information was not available from study authors. We are uncertain whether this lack of information has impacted on the results of this review. See Summary of findings for the main comparison; Summary of findings 2; Summary of findings 3 for
GRADE assessments of the quality of the evidence. Two of the trials providing IPD blinded participants and outcome assessors (Mattsson 1985; Ogunrin 2005) and the other two trials (De Silva 1996; Heller 1995) were designed as pragmatic open-label trials, as masking of treatment would not be "practicable or ethical", would "undermine compliance" and would have "introduced bias due to a very large drop-out rate." For the three trials providing withdrawal information, the withdrawal rate in the double-blinded trial (Mattsson 1985) was 40%, and withdrawal rates were 36% and 24% in De Silva 1996 and Heller 1995 respectively (29.5% withdrawal rate overall in the two open-label studies, which is statistically significantly lower than the withdrawal rate in the double-blind study; P = 0.009). It is therefore debatable whether a double-blind design is the most appropriate for trials of monotherapy in epilepsy of long duration and whether such a design does have an impact upon the dropout rate and therefore on the results of the trial.

Further differences between the studies were in the population recruited (age of participants and seizure types). We discuss these differences below in Overall completeness and applicability of evidence.

Trials for which no IPD were available were generally of poorer quality than those for which we had IPD, with two studies describing inadequate methods of randomisation or allocation concealment (Callaghan 1985; Forsythe 1991), three trials presenting incomplete outcome data following exclusion of participants (Pulliainen 1994; Ramsay 1983; Ravi Sudhir 1995), one study using an inadequate cross-over design for investigating monotherapy treatments (Cereghino 1974), and two trials providing very limited information on trial methodology, available only in abstract or summary form (Czapinski 1997; Miura 1993).

Potential biases in the review process

We were provided with IPD for 595 out of 1192 eligible participants (50%) from four out of 12 studies included; we conducted all analyses as IPD analyses. Such an approach has many advantages, such as allowing us to standardise definitions of outcomes across trials, and attrition and reporting biases being reduced as we can perform additional analyses and calculate additional outcomes from unpublished data. For the outcomes we used in this review which are of a time-to-event nature, an IPD approach is considered to be the 'gold standard' approach to analysis (Parmar 1998).

However, despite the advantages of this approach, for reasons out of our control we were not able to obtain IPD for 597 participants from eight eligible studies and no aggregate data were available for our outcomes of interest in study publications. We therefore had to exclude around half of eligible participants from our analyses, which may have introduced bias into the review.

From the results reported in these eight studies (see Table 1 for narrative description of the results of each study), only one study showed a statistically significant difference in efficacy between carbamazepine and phenytoin for participants with generalised onset seizures (73% seizure-free with phenytoin versus 39% seizure-free with carbamazepine, Callaghan 1985). There was no difference between treatments for participants with partial onset seizures (P = 0.006). Some significant differences between carbamazepine and phenytoin in terms of specific adverse events and cognitive adverse events were also reported (see Table 1). However, no consistent differences in efficacy or tolerability were reported in these eight studies, so it is unclear whether the exclusion of these studies from our meta-analysis has impacted upon our results and conclusions.

Furthermore, six of the eight studies that we could not include in meta-analysis were at high risk of bias for at least one methodological aspect (see Figure 3), so inclusion of these data may have introduced bias into our results.

We have good evidence from previous reviews conducted by the Cochrane Epilepsy Group (Marson 2000; Nolan 2013b) that misclassification of seizure type is an important issue in epilepsy trials. We believe that the results of the original trials and hence the results of this meta-analysis may have been confounded by classification bias, particularly the 48 individuals from two trials (Heller 1995; Ogunrin 2005) classified with new-onset generalised seizures over the age of 30 (Malafosse 1994). Sensitivity analysis to investigate potential misclassification of these 48 individuals changes our conclusion for two outcomes ('Time to withdrawal of allocated treatment' and 'Time to six-month remission'), and explains all heterogeneity among individuals with generalised onset seizures for the outcome 'Time to 12-month remission'. Both studies with potentially misclassified participants used the International League Against Epilepsy (ILAE) classification of 1981 (Commission 1981) to classify generalised onset and partial onset seizures. Heller 1995 was initiated before the publication of the revised ILAE classification in 1989 (Commission 1989), so some individuals in Heller 1995 may have been classified correctly according to Commission 1981 but misclassified by the revised Commission 1989. Ogunrin 2005 was initiated around 10 years after the publication of Commission 1989, but this study was conducted in Nigeria, a low-income country without access to the same facilities as trials conducted in the USA and Europe; seizure types were therefore classified clinically, and electroencephalographs (EEGs)/magnetic resonance imaging (MRI) were not required for diagnosis of epilepsy. Clinical classification may have contributed to potential misclassification in this study.

Finally, we made some assumptions in the statistical methodology used in this review. Firstly, when we received only follow-up dates and seizure frequencies, we used linear interpolation to estimate seizure times. We are aware that an individual’s seizure patterns may be non-linear; we therefore recommend caution when interpreting the numerical results of the seizure-related outcomes.

Further, the statistical methodology used in this review made an assumption that the treatment effect for each outcome did not change over time (proportional hazards assumption, see Data
synthesis). For three of the outcomes, there was evidence that this assumption may have been violated for one of the trials. Sensitivity analysis showed that changes in treatment effect tended to occur in the later stages of the studies when small participant numbers were being followed up, so small changes in treatment effect would be magnified. However, we are aware that in studies of long duration (De Silva 1996; Heller 1995; Matson 1985 followed up participants for between three and 10 years), the assumption of treatment effect remaining constant over time is unlikely to be appropriate, so if more data can be made available to us for updates of this review, we would like to perform statistical analyses which allow for treatment effects to vary over time.

**Agreements and disagreements with other studies or reviews**

No single trial included in this review has found convincing differences between phenytoin and carbamazepine with respect to seizure control or seizure type. However, CIs around estimates have been wide and equivalence cannot be inferred. Furthermore, this systematic review and meta-analysis has not found any statistically significant differences between phenytoin and carbamazepine for any of the outcome measures for all included participants. The results of this review suggest a potential advantage for phenytoin over carbamazepine for our primary global outcome ‘Time to withdrawal of allocated treatment’ for individuals with generalised onset seizures, but this result may have been confounded by misclassification of seizure type.

To our knowledge, this is the only systematic review and meta-analysis which compares phenytoin and carbamazepine for any of the outcomes specified in this review; this agrees with the findings of Smith 2007, comparing all direct and indirect evidence from trials. The network meta-analysis is currently being updated to include more recently published studies such as Ogunrin 2005, so we will compare the results of this review with the updated network meta-analysis.

**Authors’ conclusions**

**Implications for practice**

Current guidelines recommend carbamazepine or lamotrigin as first-line treatment for adults and children with new-onset partial seizures and sodium valproate for adults and children with new-onset generalised seizures (NICE 2012).

The results of this systematic review do not provide any conclusive evidence for a difference between carbamazepine and phenytoin in terms of efficacy for individuals with partial onset or generalised onset seizures. Phenytoin is no longer considered to be a first-line treatment in the USA and Europe, due to concerns over adverse events (Wallace 1997; Wilder 1995), but the results of this review show that among 589 participants from four studies conducted in the USA and Europe carbamazepine was around twice as likely to be withdrawn as phenytoin due to adverse events. Furthermore, from a study conducted in Africa (Nigeria), where phenytoin is still commonly used as a first-line treatment due to low cost, no participants withdrew from either carbamazepine or phenytoin due to adverse events. The results of this review provide no evidence in favour of the withdrawal of phenytoin as a first-line treatment.

The results of this review do not provide sufficient evidence to choose between carbamazepine and phenytoin for the treatment of partial onset or generalised onset seizures.

**Implications for research**

We found few consistent differences in efficacy between the two standard antiepileptic drugs in individual trials and from the pooled results of this review. If differences in efficacy do exist across heterogeneous populations of individuals such as those studied here, then it is likely that these differences are small. It has been argued that future comparative antiepileptic drug trials should be powered to establish equivalence (Jones 1996), and therefore be capable of detecting what is considered to be the smallest important clinical difference.

This review highlights the need for future antiepileptic drug monotherapy trials that recruit individuals of all ages with specific epilepsy syndromes, to be designed and powered to detect a difference between particular antiepileptic drugs. An approach likely to reflect and inform clinical practice, as well as being statistically powerful, would be to recruit heterogeneous populations for whom epilepsy syndromes have been adequately defined, with testing for interactions between treatment and epilepsy syndrome. In view of the potential problems of misclassification, syndromes will have to be well defined, with adequate checking mechanisms to ensure that classifications are accurate, and with a system to recognise uncertainty surrounding epilepsy syndromes in individuals within trials.

Consideration is also required in the design of a trial about whether to blind participants and outcome assessors to treatment allocation. Results of this review show that withdrawal rates are higher in a double-blind trial compared to open-label, more pragmatic trials. However, in trials involving drugs with documented adverse event profiles, such as phenytoin, masking of treatment may be important to avoid preconceptions about the drug being more likely to be associated with serious adverse events, which were not shown in the results of this review.
Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

The choice of outcomes at the design stage of a trial, and the presentation of the results of outcomes, particularly of a time-to-event nature, require very careful consideration. While an outcome measuring efficacy (seizure control), and an outcome measuring tolerability (adverse events) are recorded in the majority of studies of a monotherapy design, there is little uniformity between the definition of the outcomes and the reporting of the summary statistics related to the outcomes (Nolan 2013a), making an aggregate data approach to meta-analysis in reviews of monotherapy studies impossible. Where trial authors cannot or will not make IPD available for analysis, we are left with no choice but to exclude a proportion of relevant evidence from the review, which will impact upon the interpretation of results of the review and applicability of the evidence and conclusions. The International League Against Epilepsy (Commission 1998; ILAE 2006) recommends that studies of a monotherapy design should adopt a primary effectiveness outcome of ‘Time to withdrawal of allocated treatment (retention time)’ and should be of at least 48 weeks duration to allow for assessment of longer-term outcomes such as remission. If studies followed these recommendations, an aggregate data approach to meta-analysis may be feasible, reducing the resources and time required for an IPD approach.

A network meta-analysis has been published (Tudur Smith 2007), comparing all direct and indirect evidence from phenytoin, carbamazepine and other standard and new antiepileptic drugs licensed for monotherapy. This review and the network meta-analysis will be updated as more information becomes available. However, we acknowledge that as phenytoin is no longer considered to be a first-line agent for newly-diagnosed individuals, (with newer agents such as lamotrigine and levetiracetam replacing its use), it is unlikely that substantial new evidence will become available for this review.

ACKNOWLEDGEMENTS

We are greatly indebted to all of the original trialists that have provided individual participant data (IPD) and input into this review.

We are grateful to the Cochrane Epilepsy Group Information Scientist, Graham Chan, for performing all electronic searches.

We acknowledge Paula Williamson and Helen Clough for contributions to the original review.

REFERENCES

References to studies included in this review

Callaghan 1985 [published data only]

Cereghino 1974 [published data only]


Czapinski 1997 [published data only]

De Silva 1996 [published and unpublished data]

Forsythe 1991 [published data only]

Heller 1995 [published and unpublished data]
References to studies excluded from this review

Bird 1966 [published data only]

Bittencourt 1993 [published data only]

Canadian Study 1998 [published data only]

Canadian Study Group for Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia 1998; 39(9): 952–9.

Hakami 2012 [published data only]

Kaminow 2003 [published data only]

Martinez W, Kaminow L, Nanny KP, Hammer AE, Barrett PS. Evaluation of lamotrigine versus carbamazepine, phenytoin, or divalproex sodium as monotherapy for epilepsy patients who failed or could not tolerate previous antiepileptic drug therapy. Epilepsia 2000; 41(Suppl 7):100.

Kosteljanetz 1979 [published data only]

Kuzuya 1993 [published data only]

Rajotte 1967 [published data only]

Sabers 1995 [published data only]

Shakir 1980 [published data only]

Shorvon 1978 [published data only]

Simonsen 1976 [published data only]

Simonsen N, Olsen PZ, Kuhl V, Lund M, Wendelboe J. A double blind study of carbamazepine and diphenylhydantoin

Troupin 1975 **(published data only)**


Zeng 2010 **(published data only)**


References to studies awaiting assessment

Rysz 1994 **(published data only)**


Additional references

Annegers 1999


Carl 1992


Cockerell 1995


Commission 1981


Commission 1989


Commission 1998


Gladstone 1992


GRADE 2004


Granger 1995


Gruber 1962


Hauser 1993


Higgins 2003


Higgins 2011


Hirtz 2007


ILAE 2006


Jones 1996

Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Juul-Jenson 1983

Kirkham 2010

Kwan 2000

Lefebvre 2011

Liporace 1994

MacDonald 2000

Malafosse 1994

Marson 2000

Matlow 2012

Meador 2008

Moher 2009

Morrow 2006

Murray 1994

Ngugi 2010

NICE 2012

Nolan 2013a

Nolan 2013b

Nulman 1997

Olafsson 2005

Pal 1998

Parmar 1998

**Sander 1996**

**Sander 2004**

**Scheinfeld 2003**

**Shields 1983**

**Snead 1985**

**Stata 2009 [Computer program]**

**Tennis 1997**

**Tudur Smith 2007**

**Wallace 1997**

**Wilder 1995**

**Williamson 2002**

**Willow 1985**

**References to other published versions of this review**

**Nolan 2015**

**Tudur Smith 2002**

**Tudur Smith 2010**

**Wilson 2000**

* Indicates the major publication for the study
## Characteristics of included studies  
[ordered by study ID]

### Callaghan 1985

### Methods
- Single-centre, randomised, parallel-group trial of people referred for assessment at Cork Regional Hospital, Ireland
- Three treatment arms: carbamazepine, phenytoin, sodium valproate
- Dates conducted: Not stated

### Participants
- Adults and children with a minimum of 2 untreated generalised or partial seizures in the 6 months preceding the study
- Number randomised: PHT = 58, CBZ = 59
- 52 participants (44%) with partial epilepsy. 61 (52%) men
- Age range: 4 to 75 years. Duration of treatment (range in months): 3 to 47

### Interventions
- Monotherapy with PHT or CBZ
- Mean daily dose achieved: PHT = 5.4 mg/kg, CBZ = 10.9 mg/kg

### Outcomes
- Seizure control:
  - excellent (complete freedom of seizures)
  - good (> 50% reduction in seizure frequency)
  - poor (< 50% reduction in seizure frequency or no response)
- Side effects

### Notes
- Outcomes chosen for this review were not reported. IPD not available
- Funding: Grants provided by Labaz, Geigy, and Warner-Lambert.
- Conflicts of interest: None stated

## Risk of bias

### Bias
<table>
<thead>
<tr>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Random sequence generation (selection bias)</strong></td>
<td>Unclear risk</td>
</tr>
<tr>
<td><strong>Allocation concealment (selection bias)</strong></td>
<td>High risk</td>
</tr>
<tr>
<td><strong>Blinding of participants and personnel (performance bias)</strong></td>
<td>Unclear risk</td>
</tr>
</tbody>
</table>

---

Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Callaghan 1985

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of outcome assessment</td>
<td>Unclear risk</td>
<td>No information provided</td>
</tr>
<tr>
<td>(detection bias)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data</td>
<td>Low risk</td>
<td>Attrition rates reported. Intention-to-treat approach taken, all randomised participants analysed</td>
</tr>
<tr>
<td>(attrition bias)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>Primary outcomes (seizure control) and secondary outcomes (side effects) reported sufficiently</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other bias detected</td>
</tr>
</tbody>
</table>

### Cereghino 1974

**Methods**
- Randomised, double-blind cross-over trial with three 21-day treatment periods and 2-week washout period (regular medications used) conducted in a single centre in Newcastle, Indiana, United States
- Three treatment arms: carbamazepine, phenytoin and phenobarbitone
- Dates conducted: Not stated

**Participants**
- Institutioned adults with uncontrolled seizures on current medication
- Number randomised: PHT = 45, CBZ = 45
- 41 participants (91%) with partial epilepsy. 28 (62%) men. Age range: 18 to 51 years
- Study duration 13 weeks (3 x 21-day treatment periods plus 2 x 2-week washout periods)

**Interventions**
- Monotherapy with PHT or CBZ
- Daily dose: PHT = 300 mg/day, or CBZ = 1200 mg/day

**Outcomes**
- Behaviour outcomes
- Adverse effects
- Seizure frequency
- Time to treatment withdrawal due to poor seizure control

**Notes**
- Outcomes chosen for this review were not reported due to cross-over design
- Funding: Supported in part by an NIH research contract
- Conflicts of interest: None stated

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Randomisation of groups from random number tables (confirmed by author)</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>No information provided</td>
</tr>
</tbody>
</table>
### Cereghino 1974

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Unclear risk</th>
<th>No information provided</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>No information provided</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>No information provided</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Unclear risk</td>
<td>Withdrawal rates reported, no further information provided</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>All efficacy and tolerability outcomes specified in the Methods sections reported well in the Results section. No protocol available, outcomes for this review not available due to trial cross-over design</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other bias</td>
<td>High risk</td>
<td>Cross-over design may not be appropriate for monotherapy designs, likely carry-over effects from 1 period to another, so the comparison may not be entirely monotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Czapinski 1997

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Low risk</th>
<th>Low risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>36-month randomised, comparative study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Four treatment arms: carbamazepine, sodium valproate, phenytoin, phenobarbitone</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Dates conducted and country: Not stated (assumed conducted in Poland due to author affiliations)</td>
<td></td>
</tr>
<tr>
<td>Participants</td>
<td>Adults with newly-diagnosed epilepsy</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Number randomised: CBZ = 30, PHT = 30</td>
<td></td>
</tr>
<tr>
<td></td>
<td>100% partial epilepsy, Age range: 18 to 40 years</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Percentage men and range of follow-up not mentioned (outcome recorded at 3 years)</td>
<td></td>
</tr>
<tr>
<td>Interventions</td>
<td>Monotherapy with PHT or CBZ</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Starting doses CBZ = 400 mg/day, PHT = 200 mg/day. Dose achieved not stated</td>
<td></td>
</tr>
<tr>
<td>Outcomes</td>
<td>Proportion achieving 24-month remission at 3 years and exclusions after randomisation due to adverse effects or no efficacy</td>
<td></td>
</tr>
<tr>
<td>Notes</td>
<td>Abstract only. Outcomes chosen for this review were not reported, IPD pledged but not received</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Funding: Not stated</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Conflicts of interest: None stated</td>
<td></td>
</tr>
</tbody>
</table>
### Czapinski 1997

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Study randomised but no further information provided</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>No information provided</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>No information provided</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>No information provided</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Unclear risk</td>
<td>&quot;Exclusion rates&quot; reported for all treatment groups, no further information provided</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>No protocol available, study available in abstract format only. Outcomes for this review not available</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other bias detected</td>
</tr>
</tbody>
</table>

### De Silva 1996

<table>
<thead>
<tr>
<th>Methods</th>
<th>Randomised, parallel-group, open-label paediatric study conducted in 2 centres in the United Kingdom Trial conducted between 1981 and 1987 Four treatment arms: carbamazepine, sodium valproate, phenytoin, phenobarbitone</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>Children with newly-diagnosed epilepsy (2 or more untreated partial or generalised tonic-clonic seizures in the 12 months preceding the study) Number randomised: CBZ = 54, PHT = 54 64 children (59%) with partial epilepsy. 59 (55%) boys. Mean age (range): 9 (3 to 16) years Range of follow-up: 3 to 88 (months)</td>
</tr>
<tr>
<td>Interventions</td>
<td>Monotherapy with PHT or CBZ. Median daily dose achieved: PHT = 175 mg/day, CBZ = 400 mg/day</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Time to first seizure recurrence after start of therapy Time to 12-month remission from all seizures Adverse effects and withdrawals due to adverse events</td>
</tr>
<tr>
<td>Notes</td>
<td>IPD provided for all randomised participants. All outcomes in this review calculated from IPD Funding: support provided by the Medical Research Council, the Health Promotion</td>
</tr>
</tbody>
</table>
### Forsythe 1991

**Methods**
- Single-centre, randomised, parallel-group trial.
- Three treatment arms: carbamazepine, phenytoin, sodium valproate
- Dates conducted and country: Not stated (assumed conducted in United Kingdom due to author affiliations)

**Participants**
- Children with at least 3 newly-diagnosed generalised or partial seizures within a period of 6 months
- Number randomised: PHT = 20, CBZ = 23
- No information on epilepsy type, sex or range of follow-up
- Age range: 5 to 14 years. Study duration: 12 months

**Interventions**
- Monotherapy with PHT or CBZ
- Mean dose: PHT = 6.1 mg/day, CBZ = 17.9 mg/day
Outcomes

Cognitive assessments
Summary of withdrawals from randomised drug.

Notes

Outcomes chosen for this review were not reported
IPD not available, but could be constructed from the publication for the outcome 'Time
to withdrawal of allocated drug'
Funding: A grant was obtained from the Yorkshire Regional Health Authority, support
for measuring serum levels provided by Ciba-Geigy PLC and Sanofi PLC
Conflicts of interest: None stated

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>High risk</td>
<td>Quota allocation by sex, age, seizure type and current treatment is an inadequate randomisation method</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>No information provided</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>High risk</td>
<td>Personnel and participants (and parents) unblinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>Outcome assessors single-blinded for cognitive testing</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>Attrition rates reported, results reported and analysed for all participants randomised and all who completed various stages of follow-up</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>1 of 4 outcomes for this review reported. Cognitive outcomes described in Methods section well reported in Results section. Adverse effects reported, no seizure outcomes reported and outcomes chosen for this review not reported. No protocol available so unclear if seizure outcomes were planned a priori</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other bias detected</td>
</tr>
</tbody>
</table>
**Methods**

Randomised, parallel-group, open-label paediatric study conducted in 2 centres in the United Kingdom.
Trial conducted between 1981 and 1987.
Four treatment arms: carbamazepine, sodium valproate, phenytoin, phenobarbitone.

**Participants**

Adults with newly-diagnosed epilepsy (2 or more untreated partial or generalised tonic-clonic seizures in the 12 months preceding the study).
Number randomised: CBZ = 61, PHT = 63
52 participants (42%) with partial epilepsy. 64 (52%) men. Mean age (range): 31 (13 to 72) years.
Range of follow-up (months): 1 to 91.

**Interventions**

Monotherapy with PHT or CBZ. Median daily dose achieved: PHT = 300 mg/day, CBZ = 600 mg/day.

**Outcomes**

Time to first seizure recurrence after start of therapy.
Time to 12-month remission from all seizures.
Adverse effects and withdrawals due to adverse events.

**Notes**

IPD provided for all randomised participants. All outcomes in this review calculated from IPD.
Funding: support provided by the Medical Research Council, the Health Promotion Trust, Ciba-Geigy, Parke-Davis, and Sanofi.
Conflicts of interest: None stated.

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Randomisation list generated using permuted blocks of size 8 or 16 with stratification for centre, seizure type and presence of neurological signs.</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Allocation concealed via 4 batches of concealed opaque envelopes.</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Unclear risk</td>
<td>Unblinded; authors state masking of treatment would not be “practical” and would have “introduced bias due to a very large drop-out rate.” Unclear if outcome was influenced.</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Unblinded; authors state masking of treatment would not be “practical” and would have “introduced bias due to a very large drop-out rate.” Unclear if outcome was influenced.</td>
</tr>
</tbody>
</table>
### Mattson 1985

**Methods**
- Multicentre, randomised, parallel-group, double-blinded study over 10 centres in the USA with separate randomisation schemes used for each seizure type.
- Four treatment arms: carbamazepine, phenytoin, phenobarbital, primidone.
- Dates conducted: Not stated.

**Participants**
- Adults with previously untreated or under-treated simple or complex partial or secondary generalised tonic-clonic seizures.
- Number randomised: PHT = 165, CBZ = 155.
- 100% partial epilepsy. 278 (87%) men. Mean age (range): 41 (18 to 82) years.
- Range of follow-up: 0 to 66 months.

**Interventions**
- Monotherapy with PHT or CBZ. Median daily dose achieved: PHT = 400 mg/day, CBZ = 800 mg/day.

**Outcomes**
- Participant retention/time to drug failure (length of time participant continued to take randomised drug).
- Composite scores of seizure frequency (seizure rates and total seizure control) and toxicity.
- Incidence of side effects.

**Notes**
- IPD provided for all randomised participants. All outcomes in this review calculated from IPD.
- Funding: supported by the Veterans Administration Medical Research Service Cooperative Studies Program (CS 118).
- Conflicts of interest: None stated.

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Participants randomised with stratification for seizure type. Method of randomisation not stated and not provided by authors</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>No information provided in the publication or by study authors</td>
</tr>
</tbody>
</table>
### Mattson 1985 (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Author's judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>Double-blind (participants and personnel) achieved using an additional blank tablet</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Unclear risk</td>
<td>Unclear if outcome assessment was blinded, no information provided</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>Attrition rates reported, all randomised participants analysed from IPD provided¹</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>All outcomes reported or calculated with IPD provided¹</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other bias detected</td>
</tr>
</tbody>
</table>

### Miura 1993

<table>
<thead>
<tr>
<th>Bias</th>
<th>Author's judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methods</td>
<td>Prospective randomised study. Three treatment arms: carbamazepine, phenytoin and sodium valproate Dates conducted and country: Not stated (assumed conducted in Japan due to author affiliation)</td>
<td></td>
</tr>
<tr>
<td>Participants</td>
<td>Children aged 1 to 14 with previously untreated partial seizures and/or generalised tonic-clonic seizures Number randomised: PHT = 51, CBZ = 66. 84 (72%) with partial seizures. No information on gender Range of follow-up: 6 to 66 months, mean follow-up: 37 months in PHT group, 34 in CBZ group</td>
<td></td>
</tr>
<tr>
<td>Interventions</td>
<td>Monotherapy with PHT or CBZ. Initial daily dose: PHT = 7.2 ± 1.4 mg/kg/day, CBZ = 13.0 ± 1.6 mg/kg/day</td>
<td></td>
</tr>
<tr>
<td>Outcomes</td>
<td>Proportion of all randomised participants with seizure recurrence (by seizure type) Proportion of participants with optimum plasma levels with seizure recurrence (by seizure type)</td>
<td></td>
</tr>
<tr>
<td>Notes</td>
<td>Very limited information available. The study is reported in a summary publication of 3 different studies (other 2 studies are not CBZ vs PHT). Outcomes chosen for this review were not reported, and IPD not available Funding: Not stated Conflicts of interest: None stated</td>
<td></td>
</tr>
</tbody>
</table>
### Miura 1993  (Continued)

<table>
<thead>
<tr>
<th>Bias Type</th>
<th>Risk Assessment</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Study is described as &quot;randomised&quot; but no further details are provided</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>No information provided</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>No information provided; unclear if the study was blinded or not</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Unclear risk</td>
<td>No information provided; unclear if the study was blinded or not</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>Low risk</td>
<td>Ranges of follow-up given for both treatment groups. Results reported &quot;at the end of follow up,&quot; no withdrawals or exclusions mentioned, all participants included in analysis</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Seizure recurrence outcomes described and well reported. No adverse events reported; no protocol available so unclear if adverse events were planned a priori. Outcomes for this review not available</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other bias detected</td>
</tr>
</tbody>
</table>

### Ogunrin 2005

<table>
<thead>
<tr>
<th>Methods</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Double-blinded, parallel-group, randomised study conducted in a single centre in Nigeria between October 2000 and October 2002</td>
<td></td>
</tr>
<tr>
<td>Three treatment arms: carbamazepine, phenytoin, phenobarbitone</td>
<td></td>
</tr>
<tr>
<td>Participants</td>
<td>Consecutive newly-diagnosed people aged 14 or over presenting at the outpatient neurology clinic of the University Teaching Hospital, Benin City, Nigeria with recurrent, untreated afebrile seizures</td>
</tr>
<tr>
<td>Number randomised: PHT = 19, CBZ = 19</td>
<td></td>
</tr>
<tr>
<td>8 participants with partial seizures (22%), 23 men (62%). Mean age (range): 29.8 years (14 to 38 years)</td>
<td></td>
</tr>
<tr>
<td>All participants followed up for 12 weeks</td>
<td></td>
</tr>
<tr>
<td>Interventions</td>
<td>Monotherapy with PHT or CBZ. Median daily dose (range): PHT = 200 mg (100 to 300 mg), CBZ = 600 mg (400 to 1200 mg)</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Cognitive measures (reaction times, mental speed, memory, attention)</td>
</tr>
</tbody>
</table>
Notes
IPD provided for all randomised participants. Study duration was 12 weeks; all participants completed the study without withdrawing, so outcomes 'Time to withdrawal of allocated drug', 'Time to six-month remission' and 'Time to 12-month remission' could not be calculated. 'Time to first seizure' calculated from IPD provided
Funding: Not stated
Conflicts of interest: None stated

Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Low risk</td>
<td>Study randomised using simple randomisation. Each participant was asked to pick 1 from a table of numbers (1 - 60), numbers corresponded to allocation of 1 of 3 drugs (information provided by author)</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Low risk</td>
<td>Recruitment/randomisation of participants and allocation of treatments took place on different sites (information provided by author)</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias) All outcomes</td>
<td>Low risk</td>
<td>Participants single-blinded. Research assistant recruiting participants and counselling on medication adherence was not blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias) All outcomes</td>
<td>Low risk</td>
<td>Investigators performing cognitive assessments were single-blinded</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias) All outcomes</td>
<td>Low risk</td>
<td>All randomised participants completed the study. All randomised participants analysed from IPD provided</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>1 outcome for this review calculated from IPD provided. Other outcomes for this review not available due to short study length. All cognitive outcomes from the study well reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Low risk</td>
<td>No other bias detected</td>
</tr>
</tbody>
</table>
**Methods**

Single-centre, randomised, parallel-group trial of participants, referrals to the outpatient department of neurology of the Central Hospital of Paijat-Hame, Finland

Two treatment arms: carbamazepine and phenytoin

Dates conducted: Not stated

**Participants**

Adults (eligible age range 15 to 57) with newly-diagnosed epilepsy

Number randomised: PHT = 20, CBZ = 23*

10 (23%) participants with partial epilepsy. 20 (47%) men

Mean age (SD) years: PHT = 31.5 (11.3), CBZ = 26.8 (13.2)

**Interventions**

Monotherapy with PHT or CBZ. Dose information not reported

**Outcomes**

Cognitive assessments (visual motor speed, co-ordination, attention and concentration, verbal and visuospatial learning, visual and recognition memory, reasoning, mood, handedness)

Harmful side effects

**Notes**

*59 participants were randomised but 16 were subsequently excluded. Results were presented only for the 43 participants who completed the entire study

Outcomes chosen for this review were not reported. IPD not available

Funding: Not stated

Conflicts of interest: None stated

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
<td>Participants were randomly assigned to treatment groups, method of randomisation not stated</td>
</tr>
<tr>
<td>Allocation concealment (selection bias)</td>
<td>Unclear risk</td>
<td>No information provided</td>
</tr>
<tr>
<td>Blinding of participants and personnel (performance bias)</td>
<td>Unclear risk</td>
<td>No information provided; unclear if participants and personnel were blinded</td>
</tr>
<tr>
<td>Blinding of outcome assessment (detection bias)</td>
<td>Low risk</td>
<td>Cognitive outcome assessor was blinded</td>
</tr>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>16/59 (27%) of participants excluded from analysis. Results presented only for 43 participants who completed the study</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Unclear risk</td>
<td>Cognitive outcomes described in Methods section well reported in Results section. Adverse effects reported, no seizure outcomes reported and outcomes chosen for this review not reported. No protocol available so</td>
</tr>
</tbody>
</table>
### Pulliainen 1994

(Continued)

<table>
<thead>
<tr>
<th>Other bias</th>
<th>Low risk</th>
<th>unclear if seizure outcomes were planned a priori</th>
</tr>
</thead>
<tbody>
<tr>
<td>Low risk</td>
<td>No other bias detected</td>
<td></td>
</tr>
</tbody>
</table>

### Ramsay 1983

**Methods**

Randomised, 'two compartment' parallel study, conducted in the United States
Two treatment arms: carbamazepine and phenytoin
Dates conducted: Not stated

**Participants**

Adults, previously untreated, with at least 2 seizures or at least 1 seizure and an EEG with paroxysmal features
Number randomised: PHT = 45, CBZ = 42
55 participants (63%) with partial epilepsy. 60 (69%) men. Overall mean age (range) 37.4 (18 to 77) years
Study duration: 2 years. Range of follow-up not reported

**Interventions**

Monotherapy with PHT or CBZ
Mean daily dose achieved (for the 54 participants with no major side effects): PHT = 5.35 mg/kg/day, CBZ = 9.32 mg/kg/day

**Outcomes**

Laboratory measures
Side effects (major and minor)
Seizure control/treatment failure

**Notes**

7 participants on CBZ and 10 participants on PHT were “dropped for non-compliance” and excluded from analysis
Outcomes chosen for this review were not reported. IPD not available
Funding: Supported in part by the Southern Foundation for Brain Research
Conflicts of interest: None stated

### Risk of bias

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors' judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Random sequence generation</td>
<td>Unclear risk</td>
<td>Participants randomly assigned to treatment groups; method of randomisation not stated</td>
</tr>
<tr>
<td>Allocation concealment</td>
<td>Unclear risk</td>
<td>No information provided</td>
</tr>
<tr>
<td>Blinding of participants and personnel</td>
<td>Low risk</td>
<td>Double-blind (participants and personnel) achieved with additional blank tablet</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blinding of outcome assessment</td>
<td>Unclear risk</td>
<td>Unclear if outcome assessors were blinded</td>
</tr>
<tr>
<td>All outcomes</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### Ramsay 1983  (Continued)

<table>
<thead>
<tr>
<th>Bias</th>
<th>Authors’ judgement</th>
<th>Support for judgement</th>
</tr>
</thead>
<tbody>
<tr>
<td>Incomplete outcome data (attrition bias)</td>
<td>High risk</td>
<td>17/87 (19.5%) of participants excluded from analysis for &quot;non-compliance&quot;. Results presented only for participants who completed the study</td>
</tr>
<tr>
<td>Selective reporting (reporting bias)</td>
<td>Low risk</td>
<td>All efficacy and tolerability outcomes specified in the Methods sections reported well in the Results section. No protocol available. Outcomes chosen for this review were not reported</td>
</tr>
<tr>
<td>Other bias</td>
<td>Unclear risk</td>
<td>No other bias detected</td>
</tr>
</tbody>
</table>

### Ravi Sudhir 1995

<table>
<thead>
<tr>
<th>Methods</th>
<th>Single-centre, randomised, parallel-group study of participants referred to the Neurology Clinic of Nehru Hospital, Chandigarh, India</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Two treatment arms: carbamazepine and phenytoin</td>
</tr>
<tr>
<td>Dates conducted:</td>
<td>Not stated</td>
</tr>
</tbody>
</table>

| Participants                         | Newly-diagnosed and drug naïve adults over the age of 14 attending the Neurology Clinic of Nehru Hospital, Chandigarh, India |
|                                      | Number randomised: PHT = 20, CBZ = 20                                                                                      |
|                                      | 11 participants with partial epilepsy (27.5%), 28 men (70%)                                                                |
|                                      | Mean age (range): PHT group 23.4 (14 to 44 years), CBZ 24.4 (14 to 45 years)                                              |
|                                      | Study duration 10 to 12 weeks. Range of follow-up not reported                                                             |

| Interventions                        | Monotherapy with PHT or CBZ. Initial daily dose: PHT = 5 mg/kg/day, CBZ = 10 mg/kg/day                                 |

| Outcomes                             | Cognitive measures before and after treatments (verbal, performance, memory, visuomotor, perceptomotor organisation, visual organisation, dysfunction) |

| Notes                                 | 6 participants on CBZ and 8 participants on PHT were excluded from final analysis of cognitive assessments who were lost to follow-up or who had uncontrolled seizures |
|                                      | Outcomes chosen for this review were not reported. IPD not available                                                        |
|                                      | Funding: Not stated                                                                                                         |
|                                      | Conflicts of interest: None stated                                                                                         |

<table>
<thead>
<tr>
<th>Risk of bias</th>
<th>Risk of bias</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bias</td>
<td>Authors’ judgement</td>
</tr>
<tr>
<td>---------------------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Random sequence generation (selection bias)</td>
<td>Unclear risk</td>
</tr>
<tr>
<td></td>
<td>”The subjects were randomised to one of the two study groups,” no further information given on methods of randomisation</td>
</tr>
<tr>
<td></td>
<td>Allocation concealment (selection bias)</td>
</tr>
<tr>
<td></td>
<td>Unclear risk</td>
</tr>
<tr>
<td></td>
<td>No information provided</td>
</tr>
</tbody>
</table>
### Characteristics of excluded studies  [ordered by study ID]

<table>
<thead>
<tr>
<th>Study</th>
<th>Reason for exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bird 1966</td>
<td>Unclear whether trial is randomised and unclear whether participants received either CBZ or PHT as monotherapy. Authors could not be contacted to clarify therefore trial excluded due to uncertainties</td>
</tr>
<tr>
<td>Bittencourt 1993</td>
<td>Comparison between CBZ monotherapy and PHT monotherapy cannot be made. Participants were given phenobarbital initially which was later withdrawn whilst either CBZ or PHT was also introduced</td>
</tr>
<tr>
<td>Canadian Study 1998</td>
<td>Comparison between CBZ monotherapy and PHT monotherapy cannot be made. No randomised monotherapy comparison between CBZ and PHT. Participants were separated into 2 treatment arms (based on previous drug failure) and randomised to CBZ and clobazam in 1 arm and PHT or clobazam in the other arm</td>
</tr>
</tbody>
</table>

For studies in which IPD were provided (De Silva 1996; Heller 1995; Mattson 1985; Ogunrin 2005) attrition and reporting bias are reduced as attrition rates and unpublished outcome data are requested.

CBZ: carbamazepine  
EEG: electroencephalograph  
IPD: individual participant data  
PHT: phenytoin  

1 For studies in which IPD were provided (De Silva 1996; Heller 1995; Mattson 1985; Ogunrin 2005) attrition and reporting bias are reduced as attrition rates and unpublished outcome data are requested.
<table>
<thead>
<tr>
<th>Study</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hakami 2012</td>
<td>Comparison between CBZ monotherapy and PHT monotherapy cannot be made. Participants who failed CBZ or PHT monotherapy were randomised to levetiracetam or VPS monotherapy</td>
</tr>
<tr>
<td>Kaminow 2003</td>
<td>Participants were randomised to lamotrigine or 'standard therapy' (PHT, CBZ or VPA at the choice of the investigator). No randomised comparison can be made of CBZ and PHT</td>
</tr>
<tr>
<td>Kosteljanetz 1979</td>
<td>Comparison between CBZ monotherapy and PHT monotherapy cannot be made. All medication except phenobarbital and primidone were discontinued gradually, whilst dose of randomised drug CBZ or PHT was increased</td>
</tr>
<tr>
<td>Kuzuya 1993</td>
<td>Study is not randomised; participants were already on CBZ or PHT monotherapy on entry into the study</td>
</tr>
<tr>
<td>Rajotte 1967</td>
<td>Unclear if the study was randomised. Comparison between CBZ monotherapy and PHT monotherapy cannot be made. The trial has a cross-over design with a 2-week washout period in which both drugs were taken to make a gradual transition</td>
</tr>
<tr>
<td>Sabers 1995</td>
<td>Not fully randomised: “The treatment was chosen at random unless the individual diagnoses required a specific drug”</td>
</tr>
<tr>
<td>Shakir 1980</td>
<td>Direct comparison between CBZ and PHT not available. The publication reports 2 separate randomised studies, the first compares VPS and PHT and the second compares VPS and CBZ</td>
</tr>
<tr>
<td>Shorvon 1978</td>
<td>Study is not randomised</td>
</tr>
<tr>
<td>Simonsen 1976</td>
<td>Randomised participants were slowly withdrawn from their previous treatment as part of the trial and therefore a comparison between CBZ and PHT monotherapy cannot be made</td>
</tr>
<tr>
<td>Troupin 1975</td>
<td>All participants received PHT for 2 months prior to entering a randomised cross-over period. It is unclear whether a comparison between CBZ and PHT monotherapy could be made</td>
</tr>
<tr>
<td>Zeng 2010</td>
<td>The study is not randomised - the investigator made the choice of treatment for each participant</td>
</tr>
</tbody>
</table>

CBZ: carbamazepine  
PHT: phenytoin  
VPS: sodium valproate

**Characteristics of studies awaiting assessment**  
[ordered by study ID]

**Rysz 1994**

<table>
<thead>
<tr>
<th>Methods</th>
<th>2-arm trial of carbamazepine and phenytoin. Unclear from information provided in the abstract if the study is randomised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants</td>
<td>64 participants with untreated partial (n = 9), partial complex (n = 27), partial secondary generalised (n = 22), or primary generalised seizures (n = 6)</td>
</tr>
</tbody>
</table>
**Rysz 1994** (Continued)

<table>
<thead>
<tr>
<th>Interventions</th>
<th>Monotherapy with carbamazepine or phenytoin. Unclear how many participants were allocated to each drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outcomes</td>
<td>Somatosensoric evoked potentials (mean wave amplitude, mean proximal conduction time, mean central conduction time)</td>
</tr>
<tr>
<td>Notes</td>
<td>Full-text available only in Polish; abstract available in English. Full-text is awaiting translation before eligibility can be judged</td>
</tr>
</tbody>
</table>
### Data and Analyses

Comparison 1. Carbamazepine versus phenytoin

<table>
<thead>
<tr>
<th>Outcome or subgroup title</th>
<th>No. of studies</th>
<th>No. of participants</th>
<th>Statistical method</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time to withdrawal of allocated treatment</td>
<td>4</td>
<td>589</td>
<td>Hazard Ratio (Fixed, 95% CI)</td>
<td>0.99 [0.75, 1.30]</td>
</tr>
<tr>
<td>Time to withdrawal of allocated treatment - stratified by epilepsy type</td>
<td>2.1 Partial onset</td>
<td>3</td>
<td>428</td>
<td>Hazard Ratio (Fixed, 95% CI)</td>
</tr>
<tr>
<td></td>
<td>2.2 Generalised seizures</td>
<td>2</td>
<td>118</td>
<td>Hazard Ratio (Fixed, 95% CI)</td>
</tr>
<tr>
<td>Time to achieve 12-month remission</td>
<td>3</td>
<td>551</td>
<td>Hazard Ratio (Fixed, 95% CI)</td>
<td>0.99 [0.79, 1.25]</td>
</tr>
<tr>
<td>Time to achieve 12-month remission - stratified by epilepsy type</td>
<td>4.1 Partial onset</td>
<td>3</td>
<td>430</td>
<td>Hazard Ratio (Random, 95% CI)</td>
</tr>
<tr>
<td></td>
<td>4.2 Generalised seizures</td>
<td>2</td>
<td>121</td>
<td>Hazard Ratio (Random, 95% CI)</td>
</tr>
<tr>
<td>Time to achieve six-month remission</td>
<td>3</td>
<td>551</td>
<td>Hazard Ratio (Fixed, 95% CI)</td>
<td>1.08 [0.87, 1.34]</td>
</tr>
<tr>
<td>Time to achieve six-month remission - stratified by epilepsy type</td>
<td>6.1 Partial onset</td>
<td>3</td>
<td>430</td>
<td>Hazard Ratio (Fixed, 95% CI)</td>
</tr>
<tr>
<td></td>
<td>6.2 Generalised seizures</td>
<td>2</td>
<td>121</td>
<td>Hazard Ratio (Fixed, 95% CI)</td>
</tr>
<tr>
<td>Time to first seizure post-randomisation</td>
<td>4</td>
<td>582</td>
<td>Hazard Ratio (Fixed, 95% CI)</td>
<td>0.88 [0.72, 1.08]</td>
</tr>
<tr>
<td>Time to first seizure post-randomisation - stratified by epilepsy type</td>
<td>8.1 Partial onset</td>
<td>4</td>
<td>432</td>
<td>Hazard Ratio (Fixed, 95% CI)</td>
</tr>
<tr>
<td></td>
<td>8.2 Generalised onset</td>
<td>3</td>
<td>150</td>
<td>Hazard Ratio (Fixed, 95% CI)</td>
</tr>
</tbody>
</table>
### Analysis 1.1. Comparison 1 Carbamazepine versus phenytoin, Outcome 1 Time to withdrawal of allocated treatment.

Review: Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review

Comparison: 1 Carbamazepine versus phenytoin

Outcome: 1 Time to withdrawal of allocated treatment

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Phenytoin N</th>
<th>Carbamazepine N</th>
<th>log[HR] (SE)</th>
<th>Hazard Ratio (IV, Fixed, 95% CI)</th>
<th>Weight %</th>
<th>Hazard Ratio (IV,Fixed,95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Silva 1996</td>
<td>53</td>
<td>53</td>
<td>-0.09254 (0.32917)</td>
<td>17.9 % 0.91 [ 0.48, 1.74 ]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forsythe 1991</td>
<td>20</td>
<td>23</td>
<td>-0.36895 (0.52732)</td>
<td>7.0 % 0.69 [ 0.25, 1.94 ]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heller 1995</td>
<td>61</td>
<td>60</td>
<td>-0.45985 (0.37854)</td>
<td>13.6 % 0.63 [ 0.30, 1.33 ]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mattson 1985</td>
<td>165</td>
<td>154</td>
<td>0.14791 (0.17766)</td>
<td>61.5 % 1.16 [ 0.82, 1.64 ]</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>299</strong></td>
<td><strong>290</strong></td>
<td><strong>0.01 0.1 1 10 100</strong></td>
<td><strong>100.0 % 0.99 [ 0.75, 1.30 ]</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 2.73, df = 3 (P = 0.44); I² =0.0%

Test for overall effect: Z = 0.10 (P = 0.92)

Test for subgroup differences: Not applicable

---

Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
### Analysis 1.2. Comparison 1 Carbamazepine versus phenytoin, Outcome 2 Time to withdrawal of allocated treatment - stratified by epilepsy type.

**Review:** Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review

**Comparison:** 1 Carbamazepine versus phenytoin

**Outcome:** 2 Time to withdrawal of allocated treatment - stratified by epilepsy type

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Phenytoin N (SE)</th>
<th>Carbamazepine N (SE)</th>
<th>log [Hazard Ratio] (SE)</th>
<th>Hazard Ratio IV,Fixed,95% CI</th>
<th>Weight</th>
<th>Hazard Ratio IV,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Partial onset</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Silva 1996</td>
<td>30 (0.26349)</td>
<td>28 (0.42816)</td>
<td>0.26349 (0.42816)</td>
<td>1.17 [0.56, 3.01]</td>
<td>11.7 %</td>
<td>1.17 [0.56, 3.01]</td>
</tr>
<tr>
<td>Heller 1995</td>
<td>27 (0.13268)</td>
<td>24 (0.50548)</td>
<td>0.13268 (0.50548)</td>
<td>1.14 [0.42, 3.08]</td>
<td>8.4 %</td>
<td>1.14 [0.42, 3.08]</td>
</tr>
<tr>
<td>Mattson 1985</td>
<td>165 (0.14791)</td>
<td>154 (0.17766)</td>
<td>0.14791 (0.17766)</td>
<td>1.16 [0.82, 1.64]</td>
<td>68.0 %</td>
<td>1.16 [0.82, 1.64]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>222 (18.1 %)</td>
<td>206 (18.1 %)</td>
<td>0.14791 (0.17766)</td>
<td>1.18 [0.87, 1.60]</td>
<td>88.1 %</td>
<td>1.18 [0.87, 1.60]</td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2 = 0.07$, df = 2 ($P = 0.97$); $I^2 = 0.0$

Test for overall effect: $Z = 1.04$ ($P = 0.30$)

<table>
<thead>
<tr>
<th>Generalised seizures</th>
<th>Phenytoin N (SE)</th>
<th>Carbamazepine N (SE)</th>
<th>log [Hazard Ratio] (SE)</th>
<th>Hazard Ratio IV,Fixed,95% CI</th>
<th>Weight</th>
<th>Hazard Ratio IV,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Silva 1996</td>
<td>23 (0.59522)</td>
<td>25 (0.54909)</td>
<td>-0.59522 (0.54909)</td>
<td>0.55 [0.19, 1.62]</td>
<td>7.1 %</td>
<td>0.55 [0.19, 1.62]</td>
</tr>
<tr>
<td>Heller 1995</td>
<td>34 (1.27062)</td>
<td>36 (0.66845)</td>
<td>-1.27062 (0.66845)</td>
<td>0.28 [0.08, 1.04]</td>
<td>4.8 %</td>
<td>0.28 [0.08, 1.04]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>57 (11.9 %)</td>
<td>61 (11.9 %)</td>
<td>-1.27062 (0.66845)</td>
<td>0.42 [0.18, 0.96]</td>
<td>11.9 %</td>
<td>0.42 [0.18, 0.96]</td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2 = 0.61$, df = 1 ($P = 0.43$); $I^2 = 0.0$

Test for overall effect: $Z = 2.04$ ($P = 0.041$)

| **Total (95% CI)** | 279 (100.0 %) | 267 (100.0 %) | 1.04 [0.78, 1.39] |

Heterogeneity: $\chi^2 = 5.86$, df = 4 ($P = 0.21$); $I^2 = 32$

Test for overall effect: $Z = 0.27$ ($P = 0.79$)

Test for subgroup differences: $\chi^2 = 5.18$, df = 1 ($P = 0.02$), $I^2 = 81$
### Analysis 1.3. Comparison 1 Carbamazepine versus phenytoin, Outcome 3 Time to achieve 12-month remission.

**Review:** Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review

**Comparison:** 1 Carbamazepine versus phenytoin

**Outcome:** 3 Time to achieve 12-month remission

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Phenytoin N (SE)</th>
<th>Carbamazepine N (SE)</th>
<th>log [Hazard Ratio]</th>
<th>Hazard Ratio IV</th>
<th>Fixed,95% CI</th>
<th>Weight</th>
<th>Hazard Ratio IV</th>
<th>Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Silva 1996</td>
<td>54 (0.20155)</td>
<td>54 (0.20884)</td>
<td>0.20155</td>
<td>1.22 [0.81, 1.84]</td>
<td>32.3 %</td>
<td>1.22 [0.81, 1.84]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heller 1995</td>
<td>63 (-0.09483)</td>
<td>61 (0.21657)</td>
<td>-0.09483</td>
<td>0.91 [0.59, 1.39]</td>
<td>30.1 %</td>
<td>0.91 [0.59, 1.39]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mattson 1985</td>
<td>165 (-0.11857)</td>
<td>154 (0.19378)</td>
<td>-0.11857</td>
<td>0.89 [0.61, 1.30]</td>
<td>37.6 %</td>
<td>0.89 [0.61, 1.30]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>282</td>
<td>269</td>
<td></td>
<td>100.0 %</td>
<td>0.99 [0.79, 1.25]</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2 = 1.49$, df = 2 ($p = 0.47$); $I^2 = 0.0$

Test for overall effect: $Z = 0.07$ ($p = 0.95$)

Test for subgroup differences: Not applicable
### Analysis 1.4. Comparison 1 Carbamazepine versus phenytoin, Outcome 4 Time to achieve 12-month remission - stratified by epilepsy type.

Review: Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review

Comparison: 1 Carbamazepine versus phenytoin

Outcome: 4 Time to achieve 12-month remission - stratified by epilepsy type

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Phenytoin</th>
<th>Carbamazepine</th>
<th>log [Hazard Ratio] (SE)</th>
<th>Hazard Ratio</th>
<th>Weight</th>
<th>Hazard Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N</td>
<td>N</td>
<td>IV, Random, 95% CI</td>
<td>IV, Random, 95% CI</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Partial onset</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Silva 1996</td>
<td>30</td>
<td>29</td>
<td>-0.097 (0.29098)</td>
<td></td>
<td>18.0%</td>
<td>0.91 [0.51, 1.61]</td>
</tr>
<tr>
<td>Heller 1995</td>
<td>28</td>
<td>24</td>
<td>0.17948 (0.35009)</td>
<td></td>
<td>13.0%</td>
<td>1.20 [0.60, 2.38]</td>
</tr>
<tr>
<td>Mattson 1985</td>
<td>165</td>
<td>154</td>
<td>-0.11857 (0.19378)</td>
<td></td>
<td>34.3%</td>
<td>0.89 [0.61, 1.30]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td><strong>223</strong></td>
<td><strong>207</strong></td>
<td></td>
<td></td>
<td><strong>65.4%</strong></td>
<td><strong>0.94 [0.71, 1.25]</strong></td>
</tr>
</tbody>
</table>

Heterogeneity: $\tau^2 = 0.03; \chi^2 = 0.58, df = 2 (P = 0.75); I^2 = 0.0$

Test for overall effect: $Z = 0.42 (P = 0.68)$

2 Generalised seizures

| De Silva 1996     | 24        | 25            | 0.56595 (0.31133)      |              | 16.0%  | 1.76 [0.96, 3.24] |
| Heller 1995       | 35        | 37            | -0.23967 (0.28543)     |              | 18.6%  | 0.79 [0.45, 1.38] |
| **Subtotal (95% CI)** | **59**    | **62**        |                        |              | **34.6%** | **1.17 [0.53, 2.57]** |

Heterogeneity: $\tau^2 = 0.24; \chi^2 = 3.64, df = 1 (P = 0.06); I^2 = 73$

Test for overall effect: $Z = 0.38 (P = 0.70)$

**Total (95% CI)** | **282**   | **269**       |                        |              | **100.0%** | **1.01 [0.78, 1.31]** |

Heterogeneity: $\tau^2 = 0.01; \chi^2 = 4.76, df = 4 (P = 0.31); I^2 = 16$

Test for overall effect: $Z = 0.08 (P = 0.93)$

Test for subgroup differences: $\chi^2 = 0.25, df = 1 (P = 0.62), I^2 = 0.0$
Analysis 1.5. Comparison 1 Carbamazepine versus phenytoin, Outcome 5 Time to achieve six-month remission.

Review: Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review

Comparison: 1 Carbamazepine versus phenytoin

Outcome: 5 Time to achieve six-month remission

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Phenytoin</th>
<th>Carbamazepine</th>
<th>log [Hazard Ratio] (SE)</th>
<th>Hazard Ratio IV/Fixed 95% CI</th>
<th>Weight</th>
<th>Hazard Ratio IV/Fixed 95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Silva 1996</td>
<td>54</td>
<td>54</td>
<td>0.12899 (0.20624)</td>
<td>28.2 %</td>
<td>1.14 [0.76, 1.70]</td>
<td></td>
</tr>
<tr>
<td>Heller 1995</td>
<td>63</td>
<td>61</td>
<td>-0.01768 (0.19948)</td>
<td>30.2 %</td>
<td>0.98 [0.66, 1.45]</td>
<td></td>
</tr>
<tr>
<td>Mattson 1985</td>
<td>165</td>
<td>154</td>
<td>0.11929 (0.16975)</td>
<td>41.6 %</td>
<td>1.13 [0.81, 1.57]</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>282</strong></td>
<td><strong>269</strong></td>
<td></td>
<td><strong>100.0 %</strong></td>
<td><strong>1.08 [0.87, 1.34]</strong></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2 = 0.35$, df = 2 ($P = 0.84$); $I^2 = 0.0\%$

Test for overall effect: $Z = 0.74$ ($P = 0.46$)

Test for subgroup differences: Not applicable

Favours CBZ Favours PHT
### Analysis 1.6. Comparison 1 Carbamazepine versus phenytoin, Outcome 6 Time to achieve six-month remission - stratified by epilepsy type.

**Review:** Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review

**Comparison:** 1 Carbamazepine versus phenytoin

**Outcome:** 6 Time to achieve six-month remission - stratified by epilepsy type

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Phenytoin</th>
<th>Carbamazepine</th>
<th>log [Hazard Ratio]</th>
<th>Hazard Ratio</th>
<th>Weight</th>
<th>Hazard Ratio</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>N</strong></td>
<td><strong>N</strong></td>
<td>(SE)</td>
<td>(IV,Fixed,95% CI)</td>
<td></td>
<td></td>
<td>(IV,Fixed,95% CI)</td>
</tr>
<tr>
<td><strong>1 Partial onset</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Silva 1996</td>
<td>30</td>
<td>29</td>
<td>-0.21795 (0.28725)</td>
<td></td>
<td>14.7 %</td>
<td>0.80 [0.46, 1.41]</td>
</tr>
<tr>
<td>Heller 1995</td>
<td>28</td>
<td>24</td>
<td>-0.01072 (0.3205)</td>
<td></td>
<td>11.8 %</td>
<td>0.99 [0.53, 1.85]</td>
</tr>
<tr>
<td>Mattson 1985</td>
<td>165</td>
<td>154</td>
<td>0.11929 (0.16975)</td>
<td></td>
<td>42.1 %</td>
<td>1.13 [0.81, 1.57]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>223</td>
<td>207</td>
<td></td>
<td></td>
<td></td>
<td>68.6 % [1.02, 0.79, 1.33]</td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 1.04, df = 2 (P = 0.60); I² = 0.0%

Test for overall effect: Z = 0.19 (P = 0.85)

| **2 Generalised seizures** | | |
| De Silva 1996 | 24 | 25 | 0.5671 (0.3061) | 12.9 % | 1.76 [0.97, 3.21] |
| Heller 1995  | 35 | 37 | 0.05533 (0.25392) | 18.5 % | 1.06 [0.64, 1.75] |
| **Subtotal (95% CI)** | 59 | 62 | | | 31.4 % | 1.30 [0.89, 1.92] |

Heterogeneity: Chi² = 1.65, df = 1 (P = 0.20); I² = 39%

Test for overall effect: Z = 1.35 (P = 0.18)

| **Total (95% CI)** | 282 | 269 |
| Heterogeneity: Chi² = 3.72, df = 4 (P = 0.45); I² = 0.0%
| Test for overall effect: Z = 0.91 (P = 0.36)
| Test for subgroup differences: Chi² = 1.03, df = 1 (P = 0.31); I² = 3% |
| 100.0 % | 1.11 [0.89, 1.37] |
### Analysis 1.7. Comparison 1 Carbamazepine versus phenytoin, Outcome 7 Time to first seizure post-randomisation.

**Review:** Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review

**Comparison:** 1 Carbamazepine versus phenytoin

**Outcome:** 7 Time to first seizure post-randomisation

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Phenytoin N</th>
<th>Carbamazepine N</th>
<th>log [Hazard Ratio] (SE)</th>
<th>Hazard Ratio IV,Fixed,95% CI</th>
<th>Weight</th>
<th>Hazard Ratio IV,Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>De Silva 1996</td>
<td>54</td>
<td>54</td>
<td>-0.36392 (0.20537)</td>
<td>0.69 [0.46, 1.04]</td>
<td>25.3 %</td>
<td></td>
</tr>
<tr>
<td>Heller 1995</td>
<td>63</td>
<td>61</td>
<td>0.10556 (0.20696)</td>
<td>1.11 [0.74, 1.67]</td>
<td>24.9 %</td>
<td></td>
</tr>
<tr>
<td>Mattson 1985</td>
<td>162</td>
<td>151</td>
<td>-0.05 (0.15392)</td>
<td>0.95 [0.70, 1.29]</td>
<td>45.0 %</td>
<td></td>
</tr>
<tr>
<td>Ogunrin 2005</td>
<td>18</td>
<td>19</td>
<td>-0.73609 (0.46929)</td>
<td>0.48 [0.19, 1.20]</td>
<td>4.8 %</td>
<td></td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td><strong>297</strong></td>
<td><strong>285</strong></td>
<td></td>
<td><strong>0.88 [0.72, 1.08]</strong></td>
<td><strong>100.0 %</strong></td>
<td></td>
</tr>
</tbody>
</table>

Heterogeneity: $\chi^2 = 4.53, \text{df} = 3 (P = 0.21); I^2 = 34\%$

Test for overall effect: $Z = 1.20 (P = 0.23)$

Test for subgroup differences: Not applicable
Analysis 1.8. Comparison 1 Carbamazepine versus phenytoin, Outcome 8 Time to first seizure post-randomisation - stratified by epilepsy type.

Review: Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review

Comparison: 1 Carbamazepine versus phenytoin

Outcome: 8 Time to first seizure post-randomisation - stratified by epilepsy type

<table>
<thead>
<tr>
<th>Study or subgroup</th>
<th>Phenytoin</th>
<th>Carbamazepine</th>
<th>log [Hazard Ratio] (SE)</th>
<th>Hazard Ratio IV/Fixed,95% CI</th>
<th>Weight</th>
<th>Hazard Ratio IV/Fixed,95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 Partial onset</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Silva 1996</td>
<td>30</td>
<td>29</td>
<td>-0.29341 (0.27344)</td>
<td></td>
<td>13.8 %</td>
<td>0.75 [0.44, 1.27]</td>
</tr>
<tr>
<td>Heller 1995</td>
<td>28</td>
<td>24</td>
<td>-0.13002 (0.30041)</td>
<td></td>
<td>11.4 %</td>
<td>0.88 [0.49, 1.58]</td>
</tr>
<tr>
<td>Mattson 1985</td>
<td>162</td>
<td>151</td>
<td>-0.05 (0.15392)</td>
<td></td>
<td>43.5 %</td>
<td>0.95 [0.70, 1.29]</td>
</tr>
<tr>
<td>Ogunrin 2005</td>
<td>3</td>
<td>5</td>
<td>-0.73609 (0.46929)</td>
<td></td>
<td>4.7 %</td>
<td>0.48 [0.19, 1.20]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>223</td>
<td>209</td>
<td></td>
<td></td>
<td>73.4 %</td>
<td>0.86 [0.68, 1.08]</td>
</tr>
<tr>
<td>2 Generalised onset</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Silva 1996</td>
<td>24</td>
<td>25</td>
<td>-0.46566 (0.31338)</td>
<td></td>
<td>10.5 %</td>
<td>0.63 [0.34, 1.16]</td>
</tr>
<tr>
<td>Heller 1995</td>
<td>35</td>
<td>37</td>
<td>0.22736 (0.28994)</td>
<td></td>
<td>12.3 %</td>
<td>1.26 [0.71, 2.22]</td>
</tr>
<tr>
<td>Ogunrin 2005</td>
<td>15</td>
<td>14</td>
<td>-0.65715 (0.52266)</td>
<td></td>
<td>3.8 %</td>
<td>0.52 [0.19, 1.44]</td>
</tr>
<tr>
<td><strong>Subtotal (95% CI)</strong></td>
<td>74</td>
<td>76</td>
<td></td>
<td></td>
<td>26.6 %</td>
<td>0.84 [0.57, 1.24]</td>
</tr>
<tr>
<td><strong>Total (95% CI)</strong></td>
<td>297</td>
<td>285</td>
<td></td>
<td></td>
<td>100.0 %</td>
<td>0.85 [0.70, 1.04]</td>
</tr>
</tbody>
</table>

Heterogeneity: Chi² = 2.26, df = 3 (P = 0.52); I² =0.0%
Test for overall effect: Z = 1.28 (P = 0.20)

Test for subgroup differences: Chi² = 0.01, df = 1 (P = 0.93), I² =0.0%

ADDITIONAL TABLES

Table 1. Outcomes considered and summary of results for trials with no IPD

<table>
<thead>
<tr>
<th>Trial</th>
<th>Outcomes reported</th>
<th>Summary of results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Callaghan 1985</td>
<td>1. Seizure control: excellent (seizure-free)</td>
<td>1. PHT (n = 58); CBZ (n = 59)</td>
</tr>
<tr>
<td></td>
<td>good (&gt; 50% reduction)</td>
<td>PHT: 39 (67%); CBZ: 22 (37%)</td>
</tr>
<tr>
<td></td>
<td>poor (&lt; 50% reduction)</td>
<td>PHT: 7 (12%); CBZ: 22 (37%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>PHT: 12 (21%); CBZ: 15 (25%)</td>
</tr>
</tbody>
</table>
### Table 1. Outcomes considered and summary of results for trials with no IPD (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Outcomes Considered</th>
<th>Summary of Results</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cereghino 1974</strong>&lt;br&gt;1. Behaviour measured with rating scale modified from the Ward Behaviour Rating Scale&lt;br&gt;2. Seizure control&lt;br&gt;3. Side effects&lt;br&gt;4. Withdrawals</td>
<td>1. Behavioural scores were similar on both drugs&lt;br&gt;2. No difference between CBZ and PHT in terms of seizure control&lt;br&gt;3. Gastrointestinal and “impaired function” side effects were more common on CBZ than PHT in the first few study days. Side effects of both drugs were minimal in later stages of the study&lt;br&gt;4. PHT: 21 withdrawals out of 45 participants (47%); CBZ: 27 withdrawals out of 45 participants (60%)</td>
<td></td>
</tr>
<tr>
<td><strong>Czapinski 1997</strong>&lt;br&gt;1. Proportion achieving 24-month remission at 3 years&lt;br&gt;2. Proportion excluded after randomisation due to adverse effects or no efficacy</td>
<td>1. PHT: 59%; CBZ: 62%&lt;br&gt;2. PHT: 23%; CBZ: 30%</td>
<td></td>
</tr>
<tr>
<td><strong>Forsythe 1991</strong>&lt;br&gt;1. Cognitive assessments&lt;br&gt;2. Withdrawals from randomised drug</td>
<td>1. No significant differences between the two treatment groups on any cognitive tests&lt;br&gt;2. PHT: 6 withdrawals out of 20 participants (30%); CBZ: 9 withdrawals out of 23 participants (39%)</td>
<td></td>
</tr>
<tr>
<td><strong>Miura 1993</strong>&lt;br&gt;1. Proportion of all randomised participants with seizure recurrence (by seizure type)&lt;br&gt;2. Proportion of participants with optimum plasma levels with seizure recurrence (by seizure type)</td>
<td>PHT (n = 51); CBZ (n = 66)&lt;br&gt;1. PHT (partial): 10/31 (32%); PHT (generalised): 7/20 (35%);&lt;br&gt;CBZ (partial): 21/53 (40%); CBZ (generalised): 2/13 (15%);&lt;br&gt;2. PHT (partial): 4/17 (24%); PHT (generalised): 1/8 (13%);&lt;br&gt;CBZ (partial): 4/17 (24%); CBZ (generalised): 0/7 (0%)</td>
<td></td>
</tr>
<tr>
<td><strong>Pulliainen 1994</strong>&lt;br&gt;1. Cognitive assessments (visual motor speed, co-ordination, attention and concentration, verbal and visuospatial learning, visual and recognition memory, reasoning, mood, handedness)&lt;br&gt;2. Harmful side effects</td>
<td>1. Compared to CBZ, participants on PHT became slower (motor speed of the hand) and their visual memory decreased. There was an equal decrease in negative mood (helplessness, irritability, depression) on PHT and CBZ&lt;br&gt;2. Three participants taking PHT complained of tiredness, and 1 participant taking CBZ complained of facial skin problems, another tiredness and memory problems</td>
<td></td>
</tr>
<tr>
<td><strong>Ramsay 1983</strong>&lt;br&gt;1. Side effects (major and minor)&lt;br&gt;2. Treatment failure/seizure control&lt;br&gt;3. Laboratory results</td>
<td>1. Incidence of:&lt;br&gt;• major side effects (among analysed participants): PHT 8/35 participants (23%); CBZ 8/35 participants (23%)&lt;br&gt;• minor side effects: cognitive impairment and sedation twice as likely on CBZ as PHT&lt;br&gt;• other minor side effects similar between groups&lt;br&gt;2. Treatment failures among analysed participants:</td>
<td></td>
</tr>
</tbody>
</table>
Table 1. Outcomes considered and summary of results for trials with no IPD *(Continued)*

<table>
<thead>
<tr>
<th>Trial</th>
<th>Number randomised</th>
<th>Time to withdrawal of allocated treatment</th>
<th>Time to 12-month remission</th>
<th>Time to 6-month remission</th>
<th>Time to first seizure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PHT</td>
<td>CBZ</td>
<td>Total</td>
<td>PHT</td>
<td>CBZ</td>
</tr>
<tr>
<td>De Silva 1996</td>
<td>54</td>
<td>54</td>
<td>108</td>
<td>53</td>
<td>53</td>
</tr>
<tr>
<td>Heller 1995</td>
<td>63</td>
<td>61</td>
<td>124</td>
<td>61</td>
<td>60</td>
</tr>
<tr>
<td>Mattson 1985</td>
<td>165</td>
<td>155</td>
<td>320</td>
<td>165</td>
<td>154</td>
</tr>
<tr>
<td>Forsyth 1991</td>
<td>20</td>
<td>23</td>
<td>43</td>
<td>20</td>
<td>23</td>
</tr>
<tr>
<td>Ogunrin 2005</td>
<td>18</td>
<td>19</td>
<td>37</td>
<td>Information not available</td>
<td>Information not available</td>
</tr>
<tr>
<td>Total</td>
<td>320</td>
<td>312</td>
<td>632</td>
<td>299</td>
<td>290</td>
</tr>
</tbody>
</table>

PHT 4/35 (11%); CBZ: 5/35 (14%) Seizure control (among analysed participants with no major side effects): PHT: 23/27 participants (86%); CBZ: 22/27 participants (82%) 3. Significantly lower mean LDH level at 24 weeks in CBZ participants than PHT participants (P < 0.01). Other laboratory results similar across treatment groups

**Ravi Sudhir 1995**
1. Cognitive measures (verbal, performance, memory, visuomotor, perceptomotor organisation, visual organisation, dysfunction)
2. No significant differences between any tests of cognitive function taken before treatment and after 10 - 12 weeks for both treatment groups

CBZ = carbamazepine, LDH = lactate dehydrogenase, PHT= phenytoin

Table 2. Number of participants contributing to each analysis

<table>
<thead>
<tr>
<th>Trial</th>
<th>Number randomised</th>
<th>Time to withdrawal of allocated treatment</th>
<th>Time to 12-month remission</th>
<th>Time to 6-month remission</th>
<th>Time to first seizure</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>PHT</td>
<td>CBZ</td>
<td>Total</td>
<td>PHT</td>
<td>CBZ</td>
</tr>
<tr>
<td>De Silva 1996</td>
<td>54</td>
<td>54</td>
<td>108</td>
<td>53</td>
<td>53</td>
</tr>
<tr>
<td>Heller 1995</td>
<td>63</td>
<td>61</td>
<td>124</td>
<td>61</td>
<td>60</td>
</tr>
<tr>
<td>Mattson 1985</td>
<td>165</td>
<td>155</td>
<td>320</td>
<td>165</td>
<td>154</td>
</tr>
<tr>
<td>Forsyth 1991</td>
<td>20</td>
<td>23</td>
<td>43</td>
<td>20</td>
<td>23</td>
</tr>
<tr>
<td>Ogunrin 2005</td>
<td>18</td>
<td>19</td>
<td>37</td>
<td>Information not available</td>
<td>Information not available</td>
</tr>
<tr>
<td>Total</td>
<td>320</td>
<td>312</td>
<td>632</td>
<td>299</td>
<td>290</td>
</tr>
</tbody>
</table>

Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review (Review)

Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
CBZ = carbamazepine, PHT = phenytoin

1 Individual participant data (IPD) supplied for 114 participants recruited in De Silva 1996; randomised drug not recorded in six participants. Reasons for treatment withdrawal not available for two participants (one randomised to CBZ and one to PHT); these participants are not included in analysis of Time to treatment withdrawal.

2 Reasons for treatment withdrawal not available for three participants (one randomised to CBZ and two to PHT) in Heller 1995; these participants are not included in analysis of Time to treatment withdrawal.

3 No follow-up data after randomisation available for one participant randomised to CBZ in Mattson 1985. Data on seizure recurrence not available for six additional participants (three randomised to CBZ and three to PHT); these participants are not included in the analysis of Time to first seizure.

4 IPD for Time to treatment withdrawal available in the study publication of Forsythe 1991. Data for other outcomes not available.

5 Study duration of Ogunrin 2005 is 12 weeks, so six- and 12-month remission of seizures could not be achieved and cannot therefore be calculated. All randomised participants completed the study without withdrawing from treatment, so time to treatment withdrawal cannot be analysed.

Table 3. Reasons for premature discontinuation (withdrawal of allocated treatment)

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CBZ n = 53</td>
<td>PHT n = 53</td>
<td>CBZ n = 23</td>
<td>PHT n = 20</td>
<td>CBZ n = 60</td>
</tr>
<tr>
<td>Adverse events</td>
<td>Event</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>Seizure recurrence</td>
<td>Event</td>
<td>12</td>
<td>10</td>
<td>2</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Both seizure recurrence and adverse events</td>
<td>Event</td>
<td>6</td>
<td>5</td>
<td>0</td>
<td>0</td>
<td>4</td>
</tr>
<tr>
<td>Non-compliance/participant choice</td>
<td>Event</td>
<td>0</td>
<td>0</td>
<td>3</td>
<td>4</td>
<td>0</td>
</tr>
<tr>
<td>Participant went into remission</td>
<td>Censored</td>
<td>18</td>
<td>24</td>
<td>0</td>
<td>0</td>
<td>6</td>
</tr>
</tbody>
</table>
Table 3. Reasons for premature discontinuation (withdrawal of allocated treatment)  (Continued)

<table>
<thead>
<tr>
<th>Reason for Discontinuation</th>
<th>Censored</th>
<th>0</th>
<th>0</th>
<th>0</th>
<th>0</th>
<th>0</th>
<th>26</th>
<th>19</th>
<th>26</th>
<th>19</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lost to follow-up</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Death</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4</td>
<td>5</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>16</td>
<td>11</td>
<td>16</td>
<td>11</td>
</tr>
<tr>
<td>Completed the study (did not withdraw)</td>
<td></td>
<td>14</td>
<td>12</td>
<td>14</td>
<td>14</td>
<td>37</td>
<td>38</td>
<td>53</td>
<td>57</td>
<td>118</td>
</tr>
</tbody>
</table>

n = number of individuals contributing to the outcome ‘Time to withdrawal of allocated treatment’

1 All participants in Ogunrin 2005 completed the study without withdrawing, so this study did not contribute to ‘Time to withdrawal of allocated treatment’.

2 One participant for Heller 1995 (CBZ) and two for De Silva 1996 (one PHT and one CBZ) have missing reasons for treatment withdrawal.

3 Two participants from Heller 1995 (both PHT) had missing withdrawal times and did not contribute to analysis, but reasons for withdrawal are given.

4 Death due to reasons not related to the study drug.

5 Other reasons from Mattson 1985: participants developed other medical disorders including neurological and psychiatric disorders.

Table 4. Sensitivity analysis - Epilepsy type misclassification, fixed-effect analysis

<table>
<thead>
<tr>
<th>Analysis</th>
<th>Time to withdrawal</th>
<th>Time to six-month remission</th>
<th>Time to 12-month remission*</th>
<th>Time to first seizure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Original analysis</td>
<td>P: 1.18 (0.87, 1.60) G: 0.42 (0.18, 0.96) O: 1.04 (0.78, 1.39)</td>
<td>P: 1.02 (0.79, 1.33) G: 1.30 (0.89, 1.92) O: 1.11 (0.89, 1.37)</td>
<td>P: 0.94 (0.71, 1.25) G: 1.17 (0.53, 2.57) O: 1.01 (0.78, 1.31)</td>
<td>P: 0.86 (0.68, 1.08) G: 0.84 (0.57, 1.24) O: 0.85 (0.70, 1.04)</td>
</tr>
<tr>
<td>Test for interaction</td>
<td>Chi² = 5.18; df = 1 P = 0.02; I² = 80.7%</td>
<td>Chi² = 1.03; df = 1 P = 0.31; I² = 3.4%</td>
<td>Chi² = 0.25; df = 1 P = 0.62; I² = 0%</td>
<td>Chi² = 0.01; df = 1 P = 0.93; I² = 0%</td>
</tr>
<tr>
<td>Generalised and age at onset &gt; 30 (classified as uncertain epilepsy type)</td>
<td>P: 1.18 (0.87, 1.60) G: 0.51 (0.21, 1.24) U: 0.19 (0.02, 2.14) O: 1.05 (0.79, 1.40)</td>
<td>P: 1.02 (0.79, 1.33) G: 1.69 (1.07, 2.27) U: 0.84 (0.35, 1.98) O: 1.13 (0.91, 1.41)</td>
<td>P: 0.94 (0.71, 1.25) G: 1.44 (0.90, 2.31) U: 0.52 (0.20, 1.34) O: 1.01 (0.80, 1.28)</td>
<td>P: 0.86 (0.68, 1.08) G: 0.91 (0.57, 1.46) U: 0.97 (0.43, 2.18) O: 0.88 (0.72, 1.07)</td>
</tr>
</tbody>
</table>
Table 4. Sensitivity analysis - Epilepsy type misclassification, fixed-effect analysis (Continued)

<table>
<thead>
<tr>
<th>Test for interaction</th>
<th>Chi² = 4.99; df = 2</th>
<th>Chi² = 4.01; df = 2</th>
<th>Chi² = 4.32; df = 2</th>
<th>Chi² = 0.12; df = 2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>P = 0.08; I² = 59.9%</td>
<td>P = 0.13; I² = 50.2%</td>
<td>P = 0.12; I² = 53.7%</td>
<td>P = 0.94; I² = 0%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Generalised and age at onset &gt; 30 (reclassified as partial epilepsy)</th>
<th>Test for interaction</th>
<th>P: 1.11 (0.82, 1.50)</th>
<th>G: 0.51 (0.21, 1.24)</th>
<th>O: 1.02 (0.77, 1.36)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Chi² = 2.65; df = 1</td>
<td>P: 0.10; I² = 62.3%</td>
<td>P: 0.06; I² = 72.5%</td>
<td>P: 0.83; I² = 0%</td>
</tr>
</tbody>
</table>

df = degrees of freedom of Chi² distribution, G = generalised epilepsy, O = overall (all participants), P = partial epilepsy, U = uncertain seizure type
Results are presented as pooled hazard ratio (HR) (95% confidence interval (CI)) with fixed-effect. P < 0.05 is classified as statistically significant.
29 participants from Heller 1995 reclassified to partial epilepsy or uncertain epilepsy type for outcomes 'Time to treatment withdrawal', 'Time to 12-month remission' and 'Time to 6-month remission.'
48 participants from Heller 1995 and Ogunrin 2005 reclassified to partial epilepsy or uncertain epilepsy type for outcome 'Time to first seizure.'
See Analysis 1.2; Analysis 1.4; Analysis 1.6; and Analysis 1.8 for original analyses of 'Time to treatment withdrawal', 'Time to 12-month remission', 'Time to 6-month remission' and 'Time to first seizure', all stratified by epilepsy respectively.
* Original analysis calculated with random-effects model due to substantial heterogeneity (see Analysis 1.4). Sensitivity analyses calculated with fixed-effect model as no heterogeneity is present following reclassification of 29 participants in Heller 1995.

Table 5. Adverse event data (narrative report)

<table>
<thead>
<tr>
<th>Trial</th>
<th>Adverse event data¹</th>
<th>Summary of reported results</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Carbamazepine (CBZ)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Phenytoin (PHT)</td>
</tr>
<tr>
<td>Callaghan 1985²</td>
<td>All adverse events according to drug (note: no participants withdrew due to adverse events)</td>
<td>CBZ (n = 59): drowsiness (n = 2), rash (n = 3)</td>
</tr>
<tr>
<td>Cereghino 1974²,³</td>
<td>Most frequently observed side effects</td>
<td>Gastrointestinal side effects and &quot;impaired function&quot; (general malaise). Frequency not clearly stated</td>
</tr>
<tr>
<td>Czapinski 1997⁴</td>
<td>“Exclusions” due to adverse events or no efficacy</td>
<td>Proportion “excluded”: CBZ: 30% (out of 30 randomised to CBZ)</td>
</tr>
<tr>
<td>De Silva 1996</td>
<td>“Unacceptable” adverse events leading to drug withdrawal⁵</td>
<td>CBZ (n = 54): drowsiness (n = 1), blood dyscrasia</td>
</tr>
<tr>
<td>Study</td>
<td>Description</td>
<td>CBZ (n = 61):</td>
</tr>
<tr>
<td>------------------</td>
<td>-----------------------------------------------------------------------------</td>
<td>---------------</td>
</tr>
<tr>
<td>Forsythe 1991</td>
<td>Withdrawal due to adverse events (no other adverse event data reported)</td>
<td>4 participants out of 23 randomised to CBZ withdrew for the following reasons (some withdrew for more than adverse event): slowing of mental function, headache, anorexia, nausea, abdominal pain, fatigue and drowsiness.</td>
</tr>
<tr>
<td>Heller 1995</td>
<td>“Unacceptable” adverse events leading to drug withdrawal.</td>
<td>CBZ (n = 61): drowsiness (n = 3), rash (n = 2), headache (n = 1), depression (n = 1)</td>
</tr>
<tr>
<td>Mattson 1985</td>
<td>Narrative report of ‘Adverse effects’ and ‘Serious side effects’</td>
<td>CBZ (n = 155): motor disturbance (ataxia, incoordination, nystagmus, tremor: 33%); dysmorphic and idiosyncratic side effects (gum hypertrophy, hirsutism, acne and rash: 14%); gastrointestinal problems (27%); decreased libido or impotence (13%); No serious side effects</td>
</tr>
<tr>
<td>Miura 1993</td>
<td>No adverse events reported</td>
<td>N/A</td>
</tr>
<tr>
<td>Ogunrin 2005</td>
<td>Participant reported symptomatic complaints (provided as IPD)</td>
<td>CBZ (n = 19): memory impairment (n = 9) psychomotor retardation (n = 1) inattention (n = 1) transient rash (n = 1) CBZ-induced cough (n = 1)</td>
</tr>
<tr>
<td>Pulliainen 1994</td>
<td>Participant-reported adverse events</td>
<td>1 participant on CBZ complained of facial skin problems; 1 participant on CBZ complained of tiredness and memory problems</td>
</tr>
<tr>
<td>Ramsay 1983</td>
<td>Major and minor side effects</td>
<td>CBZ (n = 35): Major side effects: rash (n = 1), pruritus (n = 1), impotence (n = 2), dizziness (n = 1),</td>
</tr>
</tbody>
</table>
Table 5. Adverse event data (narrative report) (Continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Adverse effects reported</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ravi Sudhir 1995</td>
<td>No adverse events reported</td>
</tr>
</tbody>
</table>

CBZ = carbamazepine, N/A = not available, PHT = phenytoin

1 Adverse event data are recorded as reported narratively in the publications, so exact definition of a symptom may vary. Adverse event data supplied as IPD for Ogunrin 2005. Adverse event data were not requested in original IPD requests (De Silva 1996; Heller 1995; Mattson 1985) but will be for all future IPD requests. For numbers of withdrawals due to adverse events in studies for which IPD were provided (De Silva 1996; Heller 1995; Mattson 1985) see Table 3.

2 Participants may report more than one adverse event.

3 Note that the recruited participants in Cereghino 1974 were institutionalised, so “precise nature of side effects was not always determinable.” The two most frequently occurring side effects were reported as the frequency of participants reporting the side effect on each day of the treatment period, but overall totals of participants reporting each side effect was not reported.

4 Czapinski 1997 is an abstract only, so very little information is reported.

5 Participants may have withdrawn due to adverse event alone or a combination of adverse events and poor efficacy (seizures).

**APPENDICES**

**Appendix 1. Cochrane Epilepsy Group Specialized Register Search Strategy**

#1 MeSH DESCRIPTOR Carbamazepine Explode All
#2 Carbamazepine OR Carbamazepine OR CBZ OR SPD417 OR Apo-Carbamazepine OR Arretol OR Biston OR Calepsin OR Carbagen OR Carbamazepen OR Carbatrol OR Carbazepine OR Carbelan OR Epitol OR Equecro OR Fintel OR Karbamezipin OR Lexin OR Neurotol OR Novo-Carbamaz OR Nu-Carbamazepine OR Sirtal OR Stazepin OR Stazepine OR Taro-Carbamazepine OR Tegretal OR Tegetrol OR Telesmin OR Teril OR Timonil
#3 #1 OR #2
#4 MeSH DESCRIPTOR Phenytoin Explode All
#5 Phenytoin OR Dihydantoin OR Diphenylhydantoin OR Diphenylhydratoin OR Fenitoina OR Phenytoine OR Phenytoinum OR Aleviatin OR Antisacor OR Auranile OR Causoin OR Citrullamon OR Citrulliamon OR Comital OR Comitonia OR Convul OR Danten OR Dantal OR Dantoinal OR Dantoine OR Denyl OR Di-Hydan OR Di-Lan OR Di-Phetine OR Didan OR Difenilhidantoina OR Difenin OR Difetoin OR Dihydan OR Dihycon OR Dilabid OR Dilantin OR Dillantine OR Dillantin OR Dintoin OR Dintoia OR Diphantoin OR Diphedal OR Diphedan OR Diphedan OR Diphenin OR Diphenine OR Diphenimon OR Diphenovin OR Diphenoytin OR Diphenyn OR Ditoinate OR Ekko OR Elespindon OR Enkelfel OR Epamin OR Epanutin OR Epasmin OR Eptadomin OR Eptadontin OR Eplein OR Epiferyl OR Epilance OR Epilane OR Epilantin OR Epinat OR Epised OR Eptal OR Eptom OR Fenantoin OR Fenadontin OR Fentinin OR Fenylepsin OR Fenytion OR Fenytoine OR Gerot-epilan-D OR Hidan OR Hidantina OR Hidantal OR Hidantina OR Hidantorin OR Hidantorian OR Hidatalor OR Hydantail OR Hydantain OR Hydantoin OR Hydantoinal OR Hydantin OR Hydantolin OR Ictalitis OR Idantoil OR Idantoin OR Iphenylhydantoin OR Kessodanten OR Labopial OR Lehyan OR Lepitoin OR Lepsin OR Mesantoin OR Minetoir OR Neo-Hidantoina OR Neosidantoine OR Novantoina OR...
Appendix 2. CENTRAL via CRSO search strategy

#1 MESH DESCRIPTOR Carbamazepine EXPLODE ALL TREES
#2 (biston OR carbamazepin* OR carbatrol OR cbz OR epitol OR equetro OR neurotop OR tegretol OR teril OR timonil):TI,AB,KY
#3 #1 OR #2
#4 MESH DESCRIPTOR Phenytoin EXPLODE ALL TREES
#5 (dilantin OR epanutin OR eptoin OR fenitoina OR phenytek OR phenytoin*):TI,AB,KY
#6 #4 OR #5
#7 (epilep* OR seizure* OR convuls*):TI,AB,KY
#8 MESH DESCRIPTOR Epilepsy EXPLODE ALL TREES
#9 MESH DESCRIPTOR Seizures EXPLODE ALL TREES
#10 #7 OR #8 OR #9
#11 eclampsia:TI
#12 #10 NOT #11
#13 #3 AND #6 AND #12
#14 (adjunct* OR "add-on" OR "add on" OR adjuvant* OR combination* OR polytherap*) NOT (monotherap* or alone or singl*)):TI
#15 #13 NOT #14
#16 ("Conference Abstract"):PT AND INEMBASE
#17 #15 NOT #16
#18 * NOT INMEDLINE AND 16/09/2014 TO 01/11/2016:CD
#19 #17 AND #18

Appendix 3. MEDLINE (Ovid) search strategy

The following search is based on the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE (Lefebvre 2011).

1. exp Carbamazepine/
2. (Carbamazepin$ or Carbamezepine or CBZ or SPD417 or Apo-Carbamazepine or Atretol or Biston or Calepsin or Carbagen or Carbamazepen or Carbatrol or Carbazepine or Carbelan or Epitol or Equetro or Finlepsin or Karbamazepin or Lexin or Neurotop or Novo-Carbamaz or Nu-Carbamazepine or Sirtal or Stazezin or Stazepein or Taro-Carbamazepine or Tegretal or Tegretol or Telesmin or Teril or Timonil),tw.
3. 1 or 2
4. exp Phenytoin/
5. (Phenytoin$ or Dihydantoin or Diphenylhydantoin or Diphenylhydatanoin or Fenitoina or Phenytoine or Phénytoïne or Aleviatin or Antisacer or Auranile or Causoin or Cirullamon or Citrullamon or Comital or Comitoina or Convul or Canton or Dantal or Dantional or Dantoine or Denyl or Di-Hydan or Di-Lan or Di-Phetine or Didan or Difenilhidantoïna or Difénin or Difetoiin or Dihydyan or Dihycon or Dilabid or Dilantin or Dilantine or Dillantine or Dillantin or Dintoine or Dintoina or Diphantoin or Diphedal or Diphedan or Diphenat or Diphenin or Diphenene or Dipheninum or Diphenontio or Diphenyn or Diphenylan or Ditoinate or Ekko or Elepsindon or Enkelfel or Epamin or Epanutin or Epasmir or Epdantoin or Epdantoina or Epeloin or Epelinfy or Epifeny or Epilydan or Epilan or Epilantin or Epinat or Epised or Eptid or Eptoi or Eptoin or Fenantoin or Fenidantoin or Fentoin or Fenylepsin or Fenytoin or Fenytine or Gerot-epilan-D or Hidan or Hidantil or Hidantilo or Hidantina or Hidantoin or Hindatil or Hydantal or
Appendix 4. SCOPUS Search Strategy

(((TITLE(carbamazepine OR carbamezepine OR cbz OR spd417 OR apo-carbamazepine OR atretol OR biston OR calespin OR
carben OR carbamazepen OR carbatrol OR carbazepine OR carbelan OR epitol OR equetor OR finlepsin OR karbamazepin OR lexin
OR neurotol OR novo-carbamaz OR nu-carbamazepine OR sirtal OR stazezin OR stazepine OR taro-carbamazepine OR tegretal OR
tegrol OR teresol OR teril OR timonil))) OR (ABS(carbamazepine OR carbamezepine OR cbz OR spd417 OR apo-carbamazepine
OR atretol OR biston OR calespin OR carben OR carbamazepen OR carbatrol OR carbazepine OR carbelan OR epitol OR equetor
OR finlepsin OR karbamazepin OR lexin OR neurotol OR novo-carbamaz OR nu-carbamazepine OR sirtal OR stazezin OR stazepine
OR taro-carbamazepine OR tegretal OR tegrol OR teresol OR teril OR timonil))) AND ((TITLE(phenytoin OR dihydantoin OR
diphenylhydantoin OR diphenylhydantoin OR fenitoin OR phenytoine OR phenytoinum OR aleviatin OR antiscare OR auranel OR
causoin OR citrullamon OR citrulliamon OR comital OR comitoina OR convul OR danten OR dantional OR dantoin OR durch OR
diydan OR di-lan OR di-phetine OR didan OR difenilhidantoina OR difenin OR difetoin OR difhydron OR dihycon OR dilabil OR
dilantin OR dilantine OR dillantin OR dintoin OR dintoina OR diphantoin OR diphedal OR diphedan OR diphenar OR diphenin OR
dipheline OR diphentinum OR diphentoin OR diphyloten OR diphylamon OR ditoionate OR ekko OR elpsandon OR enkelfel OR
epmolare OR epamin OR epahunin OR epasmir OR epbadantoin OR epdantoina OR epel OR epifeny OR epihydan OR epilin OR
epilantin OR epinat OR epised OR eptol OR eptoin OR fenantoin OR fenidantoin OR fentoin OR fenlyepsin OR fenyytoine OR
ferot-epilan-d OR hidan OR hidantal OR hidantilo OR hidantina OR hidantomin OR hidatral OR hydantal OR hydantoin OR
hydantol OR ictalis OR idantoli OR idantoin OR ihphenylhidantoina OR kessoden OR labopal OR lehydan OR lepitoi OR
lepisi OR lepsin OR mesantion OR minetoin OR neoshidantoina OR novantoina OR novophenytoin OR om-hidantoina OR
om-hydantoina OR oxiylan OR phanantin OR phanatine OR phenateine OR phenatine OR phenhydan OR phenydytan OR phentoin OR
phenytoin OR phentoin OR phenytye OR ritmenal OR saceril OR sanepil OR silantin OR sinergina OR sodantoh OR sodantoin OR
sodantan OR solantin OR solantion OR solantyl OR sylantoic OR tacosal OR thilophenyl OR toin OR zentralon OR zentropil OR
pht)) OR (ABS(phenytoin OR dihydantoin OR diphenylhydantoin OR diphenylhydantoin OR fenitoina OR fenitoine OR
phenytoine OR phenytoinum OR adiatin OR antiscare OR auranel OR causoin OR citrullamon OR citrulliamon OR comital OR
comitoina OR convul OR danten OR dantional OR dantoin OR danten OR daniel OR dian OR dian OR dian OR dian OR
danl OR danl OR dantional OR dantoin OR denyl OR di-hydan OR di-lan OR di-phetine OR didan OR difenilhidantoina OR
difenin OR difetoin OR difhydron OR dihycon OR dilabil OR dilantin OR dilantine OR dillantin OR dintoin OR dintoina OR
diphantoin OR diphedal OR diphedan OR diphenar OR diphenin OR dipheline OR diphentinum OR diphentoin OR diphyloten OR
ditoionate OR ekko OR elpsandon OR enkelfel OR epamin OR epahunin OR epasmir OR epbadantoin OR epdantoina OR epel
OR epifeny OR epihydan OR epilin OR epilantin OR epinat OR epped OR eptol OR eptoin OR fenantoin OR fenidantoin OR
fentoin OR fenlyepsin OR fenyytoine OR ferot-epilan-d OR hidan OR hidantal OR hidantilo OR hidantina OR
hidantomin OR hidatral OR hydantal OR hydantoin OR hydantol OR ictalis OR iandbi OR iandtoin OR ihphenylhidantoina OR
kessoden OR labopal OR lehydan OR lepitoi OR lepsin OR mesantion OR minetoin OR neoshidantoina OR novantoina OR
novophenytoin OR om-hidantoina OR om-hydantoina OR oxiylan OR phanantin OR phanatine OR phenateine OR phenatine OR
phenhydan OR phenydytan OR phentoin OR phenytoin OR phentoin OR phenytye OR ritmenal OR saceril OR sanepil OR
silantin OR sinergina OR sodantoh OR sodantoin OR sodantan OR solantin OR solantion OR solantyl OR sylantoic OR tacosal OR
thilophenyl OR toin OR zentralon OR zentropil OR pht)) OR (ABS(phenytoin OR dihydantoin OR diphenylhydantoin OR
diphenylhydantoina OR fenitoina OR fenitoine OR phenytoine OR phenytoinum OR adiatin OR antiscare OR auranel OR
causoin OR citrullamon OR citrulliamon OR comital OR comitoina OR convul OR danten OR dantional OR dantoin OR
danten OR daniel OR dian OR dian OR dian OR dian OR
danl OR danl OR dantional OR dantoin OR denyl OR di-hydan OR di-lan OR di-phetine OR didan OR difenilhidantoina OR
difenin OR difetoin OR difhydron OR dihycon OR dilabil OR dilantin OR dilantine OR dillantin OR dintoin OR dintoina OR
diphantoin OR diphedal OR diphedan OR diphenar OR diphenin OR dipheline OR diphentinum OR diphentoin OR diphyloten OR
ditoionate OR ekko OR elpsandon OR enkelfel OR epamin OR epahunin OR epasmir OR epbadantoin OR epdantoina OR epel
OR dintoin OR dintoina OR diphantoin OR diphedal OR diphenat OR diphenin OR diphenine OR dipheninum OR diphentoin OR diphentyn OR diphenylan OR ditoainate OR ekko OR elepsin OR enkelf OR epamin OR epanutin OR epasmir OR epdantoin OR epdanteine OR epelin OR epiferyl OR ephsodyan OR epilan OR epilant OR epipat OR epis OR epctal OR eptoin OR fenantoin OR fenidantoin OR fentoin OR fenylepsin OR fenyoisn OR fenyoisine OR gerot-epilan-d OR hidan OR hidantal OR hidantilo OR hidantina OR hidantomin OR hindatal OR hydantal OR hydatin OR hydantoin OR hydantoinal OR hydantol OR icatils OR idantoin OR idantoin OR idantoin OR iphenylhydantoin OR kessodanten OR labopal OR lehydan OR lep tweaking OR lepsin OR mesantoin OR minetoin OR neos hidantoina OR neosid antoina OR novantoina OR novophenytoin OR om hidantoina OR om hidantoina OR oxylan OR phanantin OR phanatine OR phentanine OR phenatine OR phenhydan OR phenhydans OR phenitoin OR phenytoin OR phenytoyn OR phenytek OR phenytex OR ritmenal OR saceril OR sinergina OR sodanthon OR sodantoin OR sodantoin OR sodantoin OR solantoin OR solantoin OR sylantoic OR tassage OR thilophenyl OR toin OR zentronal OR zentropil OR pht)) AND ((TITLE-ABS-KEY(epilep* OR "infantile spasm" OR seizure OR convuls* OR syndrome W/2 (aicardi OR angelman OR doose OR dravet OR janz OR jeavons OR "landau kellyn" OR "lennox gautier") OR ohtahara OR panayiotopoulos OR rasmussen OR rest OR "sturge weber" OR tassinari OR "unverricht lundborg" OR west)) OR "ring chromosome 20" OR "R20" OR "myoclonic encephalopathy" OR "pyridoxine dependency") AND NOT (TITLE("eclampsia") OR INDEXTERMS("eclampsia")] OR (TITLE-ABS-KEY(lafora W/4 (disease OR epilep*)) AND NOT (TITLE("dog OR canine") OR INDEXTERMS(dog OR canine)))) AND NOT (TITLE((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR "parallel group" OR crossover OR "head to head") PRE/2 (trial OR method OR procedure OR study)) OR ABS((randomiz* OR randomis* OR controlled OR placebo OR blind* OR unblind* OR "parallel group" OR crossover OR "head to head") PRE/2 (trial OR method OR procedure OR study))) AND NOT (TITLE((adjunct* OR "add-on" OR "add on" OR adjuvant* OR combination* OR polytherap*) AND NOT (monotherap* OR alone OR singl*))))

WHAT'S NEW

Last assessed as up-to-date: 1 November 2016.

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 November 2016</td>
<td>New search has been performed</td>
<td>Searches updated 1 November 2016; no new trials identified</td>
</tr>
<tr>
<td>1 November 2016</td>
<td>New citation required but conclusions have not changed</td>
<td>Conclusions are unchanged</td>
</tr>
</tbody>
</table>

HISTORY

Protocol first published: Issue 1, 2000

Review first published: Issue 2, 2002

<table>
<thead>
<tr>
<th>Date</th>
<th>Event</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>16 September 2014</td>
<td>New search has been performed</td>
<td>Searches updated 16th September 2014</td>
</tr>
<tr>
<td>16 September 2014</td>
<td>New citation required but conclusions have not changed</td>
<td>Three new studies included; conclusions remain the same</td>
</tr>
</tbody>
</table>
1 November 2010 | New search has been performed | Searches updated 1st November 2009; no new trials identified
---|---|---
12 August 2009 | Amended | Copyedits made at editorial base
23 September 2008 | Amended | Converted to new review format
26 September 2007 | New search has been performed | Searches updated 27th July 2007; no new trials identified

**CONTRIBUTIONS OF AUTHORS**

SJ Nolan assessed studies for inclusion in the review update, assessed risk of bias in all included studies, performed analyses in SAS version 9.2, Stata version 11.2 and Meta view, added survival plots and ‘Summary of findings’ tables and updated the text of the review under the supervision of C Tudur Smith and AG Marson.

C Tudur Smith was the lead author of the original review, assessed eligibility and methodological quality of original individual studies, organised and cleaned the IPD sets, performed data validation checks and statistical analyses, and co-wrote the original review.

AG Marson obtained IPD from trial investigators, provided guidance with the clinical interpretation of results, assessed eligibility and methodological quality of individual studies and co-wrote the original review.

J Weston independently assessed risk of bias in all included studies.

**DECLARATIONS OF INTEREST**

Sarah J Nevitt: none known

Anthony G Marson: A consortium of pharmaceutical companies (GSK, Eisai, UCB Pharma) funded the National Audit of Seizure Management in Hospitals (NASH) through grants paid to University of Liverpool. Professor Tony Marson is Theme Leader for Managing Complex Needs at NIHR CLAHRC NWC.

Jennifer Weston: none known

Catrin Tudur Smith: none known

**SOURCES OF SUPPORT**
Internal sources

- NHS Research & Development Programme, UK.

External sources

- Medical Research Council, UK.
- National Institute for Health Research (NIHR), UK.

This review update was supported by the National Institute for Health Research, via Cochrane Infrastructure Grant funding to the Epilepsy Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

December 2014: title was changed to specify that the review uses individual participant data (IPD).

Sensitivity analyses added, following identification of potential misclassification of seizure type. The existence of misclassification in the individual studies could not have been known at the time of writing the original protocol.

Addition of the outcome 'Time to six-month remission' for consistency with the other reviews in the series of Cochrane IPD reviews investigating pairwise monotherapy comparisons.

NOTES

Sarah J Nolan (lead author of 2015 update) is now Sarah J Nevitt

INDEX TERMS

Medical Subject Headings (MeSH)

Anticonvulsants [adverse effects; *therapeutic use]; Carbamazepine [adverse effects; *therapeutic use]; Epilepsies, Partial [*drug therapy]; Epilepsy, Generalized [*drug therapy]; Induction Chemotherapy; Phenytoin [adverse effects; *therapeutic use]; Randomized Controlled Trials as Topic; Withholding Treatment

MeSH check words

Adult; Child; Humans